TO THE MEMBERS
ICICI Prudential Life Insurance Company Limited
Your Directors have pleasure in presenting the 25th Annual Report of ICICI
Prudential Life Insurance Company Limited (the Company) with the audited statement of
accounts for the year ended March 31, 2025 (FY2025).
PERFORMANCE Industry in FY2025
During FY2025, elections in major world economies such as United States, United
Kingdom, and France resulted in leadership changes'. In India, the electorate endorsed a
third term for the incumbent government. Geopolitically, conflicts persisted in the Middle
East and Russia-Ukraine during the year. Amid these geopolitical challenges, inflation
rates in major economies witnessed declines, prompting central banks to lower interest
rates to stimulate growth amid signs of slowing economic activity.
India reported a healthy Gross Domestic Product (GDP)1 growth of 6.5% in the
first quarter of FY2025, accompanied by 7.7% growth in Private Final Consumption
Expenditure (PFCE)1 and 6.7% growth in Gross Fixed Capital Formation (GFCF)1.
However, the growth rate slowed in the second quarter to 5.6%, despite a respectable ~5.9%
increase in both PFCE and GFCF. The third quarter showed a rebound with a growth rate of
6.2%, alongside a 6.9% increase in PFCE and 5.7% in GFCF. The data indicates that the
economy benefited from strong private consumption throughout the year and investment
levels remained healthy. Preliminary estimates project that GDP will achieve a growth rate
of 6.5% in FY20251.
The size of the Indian life insurance sector was ' 8,299.29 billion on a total premium
basis in FY2024 as compared to ' 7,825.04 billion in FY2023, growth of 6.1% year-on- year2.
The new business Retail Weighted Received Premium (RWRP) for the overall industry
increased by 10.5% from '1,089.75 billion in FY2024 to '1,203.73 billion in FY2025 and
market share of private players increased from 67.8% in FY2024 to 70.6% in FY2025.
Company in FY2025
The Company's key objective is to create value for all the stakeholders namely, the
customers, employees and shareholders. Customer-centricity continues to be at the core of
everything the Company does. Its 3C framework of Customer centricity,
Competency, and Catalyst is aimed at delivering sustainable VNB3 growth by
balancing business growth, profitability, and risk and prudence. ESG aspects have also
been
integrated into the management of Company's business throughout the process. The
Company will continue to monitor its performance against this 3C framework. For
further details, please refer to the section Strategy and Performance of the Company under
Management Discussion and Analysis forming part of this Report.
Customer centricity
The Company aims to deliver superior customer value through appropriate product
propositions, seamless onboarding & sourcing, best-in-class servicing & settling
claims with utmost sensitivity & care. The Company endeavours to: Provide seamless
digital onboarding & 24x7 assistance with topnotch convenience, continue to deliver on
the claim promise with faster settlements, offer superior overall customer experience and
maintain healthy persistency ratios
Competency
The Company will continue working on its strengths of comprehensive product suite,
extensive distribution network and superior operational efficiency. The Company endeavours
to provide the right product to the right customer and offer innovative product
propositions addressing dynamic customer needs across life stages. As part of the
Company's objective to build a diversified distribution the Company endeavours to: Invest
& grow in proprietary channels, create depth & width in multi partner shops,
deeper penetration in micro markets and be the most partnerable insurer.
The Company endeavours to enable simplified & frictionless processes across the
policy life cycle. As a result of the Company's efforts in this direction, it has enabled
simplified & frictionless onboarding process by leveraging external data sources for
KYC4, financial underwriting through ecosystem enablers, advanced underwriting
and integration with new age payment technologies. The Company's claims philosophy &
framework entails easy accessibility & sensitive handling, proactive communication,
settlement of genuine claims expeditiously and zero tolerance for fraud.
Catalyst:
The Company's key to unlock the true potential of its competency and improve the
overall customer experience is through the three catalysts namely People, Technology and
Analytics
The Company endeavours to create people' edge through learning & development,
supporting environment and fairness & meritocracy. The Company continues to build
capacity for growth, deepen organisation capability and
foster alignment to strategy & culture. The Company continues to leverage
technology' to deliver value through its mobile application. The Company enables
technology right from pre-sales, onboarding & issuance, partner integration to
customer service and claims. The Company endeavours to utilise analytics' for
powering business & products, drive operational excellence and assist in risk
mitigation. The Company continues to leverage analytics to power new business, product,
customer service and claims.
The 3C strategic elements are aimed at helping the Company deliver sustainable VNB
growth by balancing business growth, profitability and risk & prudence. The Company
strives to deliver superior customer value through its core competencies of comprehensive
product suite with seamless onboarding and sourcing via diversified distribution network
and best-in-class servicing and claim settlement. The Company endeavours to strategically
leverage the synergies of people, technology, and analytics to fully realise its core
competencies and enhance the overall customer experience. The Company believes that this
3C framework is appropriate in the context of the large insurance opportunity in the
country, a facilitative regulatory regime and coupled with the objective to grow absolute
VNB.
Business Growth
The Company endeavours to grow premium through enhancing distribution, expanding
protection business, growing annuity line of business and deepening penetration in
under-served customer segments
The Company willlookto strengthen its distribution network through a closer mapping of
distribution segments with customer segments and products. The Company is also focused on
expanding the distribution network through the acquisition of new partners as well as
investing in the creation of new sourcing channels. The Company remains focused on
expanding the protection business and believes it offers strong growth opportunities.
Given the current levels of under-penetration, retail protection business growth presents
a multi-decadal opportunity, while credit life and group term business also offer
significant opportunities as we witness growth in credit and the economy. The Company
would continue to cater to the retirement savings need of customers while managing the
investment risk appropriately. The Company will continue to focus on broadening the
customer base through initiatives spanning both distribution and products.
Profitability
The Company's endeavours to achieve its core objective of increasing absolute VNB while
delivering value to our customers. It also continues to work towards aligning a cost
structure commensurate with the product mix.
The Company's Value of New Business (VNB) grew by 6.4% from ' 22.27 billion in FY2024
to ' 23.70 billion in FY2025, while its VNB margin stood at 22.8%.
The Company's cost to Total Premium stood at 18.1% whereas overall cost to Total
Weighted Received Premium
(TWRP) stood at 25.1% in FY2025. The cost to TWRP ratio for the savings business
improved from 15.8% in FY2024 to 15.4% in FY2025. The Company monitors cost ratios for the
savings line of business separately. The objective is to bring efficiency in the savings
line of business while the Company continues to focus on growth in the protection
business. The Company's cost ratios have seen an improvement quarter-on-quarter, and it is
committed to working towards aligning a cost structure commensurate with the product mix.
Risk and Prudence i
The Company continues to imbibe risk & prudence across organisational culture,
sales & processes through robust governance. Risk management is an integral part of
the Company's ecosystem with focus on right selling, right sourcing and right onboarding.
Its robust risk management architecture is exhibited in its strong and resilient balance
sheet.
Persistency experience & mortality experience monitored regularly
69.3% of liabilities largely pass on market performance to customers
Non-par guaranteed savings & annuities: Derivatives to hedge interest rate
risks
95.4% of fixed income in sovereign or AAA; 0.3% of fixed income below AA
Zero NPA since inception
Raised additional sub-debt of ' 14.00 billion, further strengthening the
solvency ratio to 212.2% as of March 31, 2025
A summary of key financial and business parameters is set out below:
(' billion)
Particulars |
FY2024 |
FY2025 |
New business |
180.81 |
225.83 |
received premium |
|
|
Annualised |
90.46 |
104.07 |
premium equivalent |
|
|
Savings including annuity |
7 5.21 |
87.69 |
Protection |
15.25 |
16.38 |
Total in-force sum |
34.1 |
39.4 |
assured (? trillion) |
|
|
13th month persistency5 |
89.0% |
89.1% |
49th month persistency5 |
70.5% |
69.5% |
Renewal premium |
245.57 |
257.20 |
Cost to total premium |
18.2% |
18.1% |
Cost to total weighted |
24.0% |
24.4% |
received premium (TWRP)6 |
|
|
Cost to TWRP (savings) |
15.8% |
15.4% |
Value of new business (VNB) |
22.27 |
23.70 |
Embedded value (EV) |
423.37 |
479.51 |
5
Regular and Limited pay persistency in accordance with IRDAI circular on
Public Disclosures by Insurers' dated September 30, 2021; 12 month rolling
persistency for March to February measured at March 31
6Total Cost including
commission/ TWRP TWRP: Total weighted received premium (Total premium - 90% of single
premium)
Outlook for the industry and the Company
The total life insurance premiums grew from ' 500.94 billion in FY2002 to ' 8,299.29
billion in FY2024 (13.6% CAGR). Additionally, new business premiums (retail weighted
received premium) grew from '116.00 billion in FY2002 to ' 1,203.73 billion in FY2025
(10.7% CAGR). According to a report by Swiss Re, between CY2025-CY2029, total life
insurance premiums in India are expected to grow at a CAGR of 6.9% in real terms, well
above the global (2.7%) and emerging economies (5.3%). At this rate, India will have the
fastest growing insurance sector of the G20 countries. With rising per capita income,
increased financial awareness, product innovation, demographic changes and favourable
regulatory reforms, the life insurance industry is poised for long term sustainable growth
in India.
Debentures issued during FY2025
During FY2025, the Company had issued 1,40,000 rated, listed, redeemable, unsecured,
subordinated, taxable, fully paid-up, non-cumulative, non-convertible debentures, as per
the details given below:
Particulars |
Issue Details |
Date of issue and allotment of the securities |
Issue Date: October 22, 2024 Allotment Date: December
19, 2024 |
Number of securities |
1,40,000 (One Lakh Forty Thousand) debentures |
Whether the issue of the securities was by way of preferential
allotment, private placement or public issue |
Private Placement |
Brief details of the debt restructuring pursuant to which the
securities are issued |
Not Applicable |
Issue price |
' 1,00,000 (Rupees One Lakh only) per debenture |
Coupon rate |
8.03% per annum |
Maturity date |
December 19, 2034 |
Amount raised |
' 14 billion |
During FY2025, the funds raised by the Company through issue of non - convertible
Debentures, have been utilized in the normal course of the business activities, including
strengthening the Company's solvency ratio.
Our Reach
The Company reaches its customers through 459 offices in 397 locations as of March 31,
2025. At March 31, 2025, the Company had 20,035 employees and 229,441 advisors to cater to
the needs of its customers. The Company distributes its products through agents, corporate
agents, banks, brokers, proprietary sales force (PSF) and online channels.
Products
Broadly, the Company's products can be categorised into savings, protection and
annuities. Savings products are offered on three platforms i.e. linked, participating and
non-participating.
These plan offers life cover as well as savings which is paid either in lump sum in
form of regular stream of income.
Protection products are available on retail, group and credit life platforms. These
products provide cover for life, disability, critical illness and accidental death.
Annuity products are available on retail and group platforms. These products provide a
regular stream of guaranteed income.
Claims
The Company settled over 368,102 mortality claims amounting to a total of ' 48.81
(Individual ' 18.14, Group ' 30.67) billion in FY2025 with individual claim settlement
ratio of 99.3% and group claim settlement ratio of 99.9%. The overall claims settlement
ratio with individual claims and group claims is 99.8%.
Further, the Company has also paid 1,41,934 maturity claims from its retail business
operations and over 4,02,254 survival benefit claims amounting to ' 95.78 billion and '
11.96 billion, respectively for FY2025. Additionally, the Company has settled 3,20,904
surrender claims from its retail business operations and 5,31,173 from group business,
amounting to a total of ' 311.65 billion.
For non-investigated retail individual death claims, the settlement was completed
within an average turnaround time of 1.2 days from the receipt of the last requirement.
Subsidiary
The Company's wholly owned unlisted subsidiary, ICICI Prudential Pension Funds
Management Company Limited (PFM) acts as a pension fund manager under the National Pension
System (NPS) with an objective of providing a strategic platform to leverage the
substantial pension opportunity in India. Further, PFM is also registered to serve as a
Point of Presence (PoP) entity for distribution of NPS products and servicing.
During FY2025, the subscriber assets managed by PFM increased by 59.9%, from ' 284.19
billion at March 31, 2024 to ' 454.55 billion at March 31, 2025. Additionally, PFM
enrolled 206,065 new subscribers during the year. The loss after tax of PFM increased from
' 17.2 million in FY2024 to a loss of ' 35.4 million in FY2025, primarily on account of
increase in IT related spending and wage cost, reflecting the expansion of capacity as
part of the overall growth plan. The overall contribution of the subsidiary to the
financial results of the Company is not significant currently. The subsidiary is committed
towards increasing its presence in the industry and is focused on scaling up the business
and revenue.
The audited financial statements of the subsidiary are available on the Company's
website (www.iciciprulife. com) and are available for inspection by any Member of
the Company at its registered office. A statement containing salient features of the
financial statements of the subsidiary company forms part of the financial statements of
the Company.
Rural and social business
Rural
The Company is aligned to the objective of Insurance for All' by 2047 and has
been allocated 1196 gram panchayats spread across the states of Tamil Nadu, Uttar Pradesh,
Bihar and Karnataka in FY2025, and is assigned the role of driving insurance penetration
through covering a certain defined percentage of population in these GPs. Against a target
of collectively attaining minimum of 10% of lives in each gram panchayat for FY2025, the
Company by itself, has ensured 10% of population coverage in each of its 1196 allocated
GPs with aggregate count of 15,44,623 lives.
Social
The Company has micro insurance products in both group and retail segments to cater to
the protection needs of the social segment, which are people working in informal or
unorganized sector and those falling in economically vulnerable section of the society.
The Company partners with micro finance institutions, banks and extends both retail and
group micro insurance cover to customers for covering their loss of income risk arising
out of unfortunate or untimely demise. Social lives covered by the Company amounts to
1,04,08,315 (11.35%) of the total lives of the Company in FY2025.
To make insurance available, affordable, and accessible to underserved section of
customers, the Company is working in lines of augmenting its product suite, exploring new
modes of distribution and increasing the width of existing distribution through addition
of partners.
FINANCIALS & AUDIT Financials
Particulars |
Standalone |
Consolidated |
|
FY2024 |
FY2025 |
FY2024 |
FY2025 |
Profit after tax |
8.52 |
11.89 |
8.51 |
11.86 |
Balance brought forward from the previous year |
48.09 |
55.75 |
48.07 |
55.71 |
Profit available for
appropriations
Appropriations: |
56.61 |
67.64 |
56.58 |
67.57 |
Interim Equity Dividend |
- |
- |
- |
- |
Final Equity Dividend |
0.86 |
0.86 |
0.86 |
0.86 |
(' billion)
Particulars |
Standalone |
Consolidated |
|
FY2024 |
FY2025 |
FY2024 |
FY2025 |
Tax on Equity Dividend Surplus carried to next year's account |
55.75 |
66.78 |
55.71 |
66.70 |
Note: Components may not add up to the totals due to rounding off
The financial position of the Company remained strong with a solvency ratio of 212.2 %
at March 31, 2025 (191.8 % at March 31, 2024) against the minimum regulatory requirement
of 150%.
Transfer to Reserves
During FY2025, profit after tax amounting to ' 11.03 billion after all adjustment and
appropriation, was carried to reserve & surplus in Balance sheet.
Dividend and dividend distribution policy
The operations have resulted in a profit after tax of ' 11.89 billion in FY2025 as
compared to a profit after tax of ' 8.52 billion for the previous year.
During the year, the Company has paid the interest on non-convertible debentures of '
12.00 billion that was raised during FY2021. The interest accrued thereafter together with
interest accrued on the subsequent non-convertible debentures of ' 14.00 billion raised
during FY2025 have been duly provided for in the books of accounts. The Company's solvency
ratio stood at 212.2 % on March 31, 2025. The Board has proposed a final dividend of '
0.85 per equity share for FY2025 amounting to ' 1.23 billion for FY2025, representing a
dividend payout ratio of 10.33% of PAT.
In terms of Regulation 43A of Listing Regulations, the Dividend Distribution Policy of
the Company is disclosed on its website https://www.iciciprulife.com/about-us/
corporate-policies.html.
Transfer of unclaimed dividend and shares to Investor Education & Protection Fund
(IEPF)
Pursuant to the provisions of Section 124 of the Companies Act, 2013 (CA2013), the
amount of dividend remaining unpaid or unclaimed for a period of seven years from the date
of its transfer to the unpaid dividend account/s' of the Company, are required to be
transferred to the Investor Education and Protection Fund (IEPF) established by the
Central Government.
During the financial year ended March 31, 2025, dividend amount of ' 2.99 million
remaining unclaimed for a period of seven years from the date of its transfer to the
unpaid dividend accounts of the Company has been transferred to IEPF.
Pursuant to Section 124(6) of the CA2013 read with the Investor Education &
Protection Fund Authority (Accounting, Audit, Transfer & Refund) Rules, 2016,
during the financial year ended March 31, 2025, 5,219 equity shares in respect of which
the dividend has not been claimed for seven consecutive years have been transferred to the
designated demat account of the IEPF Authority.
The unclaimed dividend and the equity shares transferred to IEPF can be claimed by
making an application in the prescribed form available on the website of IEPF at www.iepf.gov.in
of the Company, as per the applicable provisions of the CA2013 and the Insurance
Regulatory and Development Authority of India (Corporate Governance for Insurers)
Regulations, 2024.
Walker Chandiok & Co LLP were re-appointed as the joint statutory auditor on June
25, 2021 for a term of five years i.e. from the conclusion of the 21st Annual
General Meeting (AGM) up to the conclusion of the 26th AGM.
The unclaimed dividend for the financial year ended March 31, 2018 and March 31, 2019
shall be transferred to the IEPF in FY2026. The corresponding shares, if the dividend is
unclaimed for a period of seven years along with the unclaimed dividend shall also be
transferred to the dematerialised account of the IEPF Authority.
Members who have not yet encashed their dividend warrant(s) can claim the same in
accordance with the process made available on the website of the Company by accessing the
following link https://www.iciciprulife.
com/about-us/shareholder-information/dividends. html?ID=about-dividends
Particulars of loans, guarantees or investments
The provisions of Section 186(4) of the CA2013, requiring disclosure in the financial
statements of the full particulars of the loans given, investment made or guarantee given
or security provided including the purpose for which the loan or guarantee or security is
proposed to be utilised by the Company, are not applicable to an insurance company.
Particulars of contracts or arrangements with related parties
The particulars of contracts or arrangements entered into by the Company with related
parties referred to in sub-section (1) of Section 188 of the CA2013 are disclosed in Form
AOC -2 appended as Annexure A. Further, as per the shareholding pattern of the
Company, only ICICI Bank Limited and Prudential Corporation Holdings Limited have a
holding in the Company of 10% or more. The transactions with these entities are disclosed
in note 3.12 of related party transactions under notes to accounts.
The Company has a Board approved policy on Related Party Transactions, which has been
hosted on the website of the Company at https://www.iciciprulife.com/
about-us/corporate-policies.html.
Public deposits
During the year under review, the Company has not accepted any deposits under Section
73 of the CA2013.
AUDITORS Statutory auditors
Walker Chandiok & Co LLP, bearing registration number 001076N/N500013, Chartered
Accountants and M. P. Chitale & Co. bearing registration number 101851W, Chartered
Accountants are the joint statutory auditors
The Members at the AGM held on June 28, 2024 had appointed M. P. Chitale & Co.
bearing ICAI registration 101851W as the joint statutory auditor of the Company for a
period of four years up to the conclusion of the 28th AGM.
Fees for services to statutory auditors
The Company has incurred ' 24.0 million as statutory audit fees for the year ended
March 31, 2025. Further, the Company has not availed any other services except mentioned
below, from the statutory auditors or its network entities/affiliated firms during the
year ended March 31, 2025.
Pursuant to Master Circular on Corporate Governance for Insurers, 2024, the additional
work entrusted to the statutory auditor is given below:
Name of the Auditor |
Services rendered |
Year ended March 31, 2025 |
Year ended March 31, 2024 |
Walker |
Assurance Provider for |
1.2 |
1.0 |
Chandiok |
BRSR core report as |
|
|
& Co. LLP |
required under SEBI (Listing Obligations and Disclosure Requirements)
Regulations, 2015 |
|
|
Walker |
Review and Audit of |
0.9 |
- |
Chandiok & Co LLP |
the Group Reporting Pack, required for the consolidation of ICICI Bank's
financial statements with those of its subsidiaries |
|
|
Walker Chandiok & Co LLP |
Consent letters from auditors for specific references to
the Auditors in the KID and GID filed with SEBI and Stock exchanges in connection to issue
of non-convertible debentures amounting to ' 14.00 billion. |
0.7 |
|
|
|
|
COMPLIANCE AND RISK
Statement in respect of adequacy of internal financial controls
The Company has complied with internal financial controls (IFC) as per section-134 (5)
of CA2013 and regulation 17(8) of the Listing Regulations in terms of internal controls
over financial reporting and section 404 of Sarbanes Oxley Act (SOX), 2002. To ensure
effective internal financial controls, the Company has implemented Internal Control
Framework, 2013 endorsed by the Committee of Sponsoring Organisations (COSO) of the
Treadway Commission. The Company's internal financial control framework comprises of
internal controls over financial reporting, operating controls, and fraud prevention
controls. The framework is designed to ensure accuracy, completeness and reliability of
financial records, orderly and efficient conduct of business and safeguarding of assets as
well as prevention and detection of fraud. The Company has a mechanism of testing the
controls at regular intervals for design and operating effectiveness. Further, the
auditors opine on the adequacy and operating effectiveness of internal financial controls
over financial reporting. The Company believes that strengthening of internal controls is
an ongoing process and there will be continuous efforts to keep pace with changing
business needs and environment. The key components of the internal financial control
framework include:
Entity level controls: The control environment of the Company relies on a set of
Entity Level Controls (ELCs) that operate at an organisation level and may not be embedded
in any single process of the Company. The ELCs set up by the Company include:
(a) Corporate governance framework comprising Board and Executive committees for
oversight of the management of the Company.
(b) Policies commensurate with the Company's size and level of complexity to establish
standards of conduct, including a code of conduct, whistle blower policy, prevention of
harassment in the workplace, conflict of interest, corporate communications, insurance
awareness and customer education policy, grievance redressal policy, record maintenance
policy, delegation of financial powers, accounting policy, etc.
(c) Risk and fraud management framework to identify, measure, monitor and control
various risks including operational risks, and a framework for identifying, monitoring and
control over outsourced activities.
(d) Independent Internal Audit Department with oversight from the Audit Committee.
(e) Employee management framework comprises hiring, diversity and inclusion, retention,
training, performance evaluation, remuneration structure, compensation, succession
planning through leadership cover index, etc.
Notes:
(a) Remuneration of ' 1.0 million plus out of pocket expenses (subject to a maximum of
five (5) percent of the audit remuneration) and taxes, as applicable,- to M. P. Chitale
& Co. and Walker Chandiok & Co., LLP for review / audit of the Group Reporting
Pack for FY2026, subject to the approval of the Members at the 25th AGM
(b) Remuneration of ' 1.75 million plus out of pocket expenses (subject to a maximum of
five (5) percent of the audit remuneration) and taxes, as applicable, to M. P. Chitale
& Co. for limited review of Ind AS compliant proforma financial statements for FY2025
and FY2026, subject to the approval of the Members at the 25th AGM.
Secretarial auditors
The Company had, with the approval of its Board of Directors, appointed M/s. Alwyn Jay
& Co., Company Secretaries to undertake secretarial audit of the Company for FY2025.
The secretarial audit report is annexed herewith as Annexure B.
The Board at its meeting held on April 15, 2025, has appointed M/s. Parikh &
Associates (FRN: P1988MH009800), Company Secretaries as the Secretarial Auditor of the
Company for a period of five years i.e. from FY2026 to FY2030, subject to approval of the
members of the Company at the 25th AGM of the Company.
Auditor's report
There is no qualification, reservation or adverse remark made by both the statutory
auditors and secretarial auditors in their report. There were no reportable frauds
identified by the auditors during FY2025.
Name of the Auditor |
Services rendered |
Year ended March 31, 2025 |
Year ended March 31, 2024 |
M. P.
Chitale & Co |
Review and Audit of the Group Reporting Pack, required for the
consolidation of ICICI Bank's financial statements with those of its subsidiaries |
0.9 |
|
M. P.
Chitale & Co |
Consent letters from auditors for specific references to the Auditors in
the KID and GID filed with SEBI and Stock exchanges in connection to issue of
non-convertible debentures amounting to ' 14.00 billion. |
0.7 |
|
Total |
|
4.4 |
1.0 |
(f) Framework to ensure compliance with regulations, laws including compliance
certification, regular communication of changes in regulations/ laws, and litigation
management. Framework to ensure compliance of internal control over financial reporting.
(g) Budgeting, monitoring, and reporting of the performance with key performance
indicators.
(h) Information and cyber security policy and information security framework along with
framework to ensure business continuity and disaster recovery.
(i) Information technology governance standards and procedures to ensure delivery of
value and a secure working environment that meets legal stipulations and regulatory
guidelines.
Process controls: These comprise of controls operating at process level with the
objective of providing assurance at a transaction recording stage. The salient aspects of
the control framework include:
(a) All business processes having implications on financial results, regulatory and
shareholder reporting are subject to quarterly reviews. Any material deficiency is
discussed at the Audit Committee meetings.
(b) The Company has deployed automation in most aspects of transaction processing
(including policy administration, investment management, actuarial computations, expense
processing, claims management, human resource processes and accounting) to ensure greater
control and efficiency.
Information Technology (IT) controls: The Company has in place a robust IT control
environment including controls pertaining to change management, system & database
management, access management, master maintenance, interface, job scheduling, datacenter,
cloud management, backup and disaster recovery and cybersecurity to ensure data integrity
and accuracy of information stored in IT systems. Further the Company has been compliant
with the requirements, prescribed under amendments in the Companies (Account) Rules, 2014,
of using accounting software which has a feature of recording audit trail and creating an
edit log of each change made in the books of account.
Control over third parties providing services: The Company has a vendor on-boarding
process with due diligence, risk assessment, document review and periodic assessment to
ensure controls over third-party service providers relevant from a financial reporting
perspective. Further, the Board Risk Management Committee has oversight on the
implementation of controls and monitors the performance of the outsourced vendors.
Safeguarding of assets: The Company has adequate controls over safeguarding of
assets (comprising of investment assets, IT assets and other assets). These controls are
based on value and custody of assets.
Review controls: Review controls comprise of multiple levels of oversight over
financial reporting by way of a strong reporting and review framework as follows:
(a) The financials are audited by joint statutory auditors and are reviewed and
approved by the Audit Committee and Board. They are also submitted to the Insurance
Regulatory and Development Authority of India (IRDAI).
(b) The Internal Audit Department exercises independent oversight over operational and
financial processes. Any significant observations and recommendations are presented to the
Audit Committee. The investment operations function is subject to concurrent audit
certification and an Investment Risk Management Systems (IRMS) audit once in two years.
Any significant findings in the concurrent audit or IRMS audit are presented to the Audit
Committee.
(c) The Company has an effective organisation structure that segregates duties among
business groups, thereby, ensuring orderly and efficient conduct of business.
Additionally, the Board has constituted various committees responsible for specific
operational areas, formulation of policies and frameworks, and identification, assessment
and monitoring of principal risks in accordance with the policies and procedures.
(d) There are senior management controls comprising of high-level controls (HLC) and
management review controls (MRC) to monitor and identify any material misstatement.
Management exercises review control by way of in-depth reviews of financials, ledger
balances, suspense items and payables, liability assumptions, information security,
regulatory compliance, communication and reporting, key compliance issues, supervision of
risk management function, etc. conducted by the Chief Financial Officer, Appointed
Actuary, Head of Information Technology, Head of Operations and Head of Compliance &
Risk.
Fraud prevention: The Company has a Board approved fraud risk management policy
which is based on Insurance Fraud Monitoring Framework' guidelines issued by IRDAI.
The Company has an Operational Risk Management Committee (ORMC) which independently
monitors frauds. The ORMC reports to the Executive Risk Committee which ultimately reports
to the Board Risk Management Committee (BRMC).
(a) The fraud control framework consists of preventive measures, incident management
and awareness activities. Preventive measures include fraud risk assessment for design of
processes, investigation triggers across policy life cycle and proactive use of analytics
to identify fraud patterns. Incident management includes recovery of loss, action through
law enforcement agencies, detailed
investigation and root cause analysis, and fraud incident reporting to BRMC. Awareness
includes mandatory induction training and awareness program for employees, regular
communication to policy holders, fraud prevention tips on the Company's website, etc.
(b) The Company ensures implementation of controls to prevent repetition of incidents,
financial recovery process, and disciplinary action against involved employees. It also
initiates actions through law enforcement authorities based on severity of the incident.
(c) The Company undertakes several measures from time to time to create awareness
amongst its employees and customers against fraudulent practices.
INTERNAL AUDIT AND COMPLIANCE
FRAMEWORK
Internal audit:
The Internal Audit Department (IAD) of the Company acts as an independent entity and
reports to the Audit Committee of the Board. IAD has an unrestricted access to the Audit
Committee Chairperson and the Managing Director and Chief Executive Officer (MD &
CEO). The Head-Internal Audit reports directly to the Audit Committee of the Board and
administratively reports to the Chief Risk & Governance Officer. The IAD has developed
a Risk Based Audit Plan (RBAP) and the same has been approved by the Audit Committee of
the Board. The basic philosophy of risk-based audit framework is to provide reasonable
assurance to the Audit Committee of the Board and management about the adequacy and
effectiveness of the risk management and control framework in the Company. The scope of
Internal Audit includes the review of risk management procedures, internal control
systems, information systems and governance processes. Key audit observations and
recommendations made are reported to and discussed at the Audit Committee of the Board.
Implementation of the recommendations is actively monitored.
Compliance:
The Board Audit Committee oversees the compliance framework of the Company. The Company
has formulated various internal policies/procedures, such as the Compliance Policy, Anti-
Bribery and AntiCorruption Policy, Anti-Money Laundering Policy and an employee code of
conduct, which govern the day-to-day activities to ensure compliance. The Compliance
Function disseminates the information regarding relevant laws, regulations and circulars
related to insurance and anti-money laundering to various functions. It also serves as a
reference point for the staff of various functions for seeking clarifications on
applicable laws, regulations and circulars issued on these aspects. The compliance team
also monitors the adequacy of the compliance framework across the Company with the
Internal Audit Department through an integrated risk-based audit plan. Key issues observed
as a part of this monitoring are reported to the Board Audit Committee and implementation
of recommendations is actively monitored. A compliance certificate signed by the Managing
Director & CEO, based on the certification from respective functional heads, is placed
at the Board Audit Committee and Board of Directors meetings on a quarterly basis.
Risk management
The Company recognises that risk is an integral element of the business and managed
acceptance of risk is essential for generating shareholder value.
The risk governance structure of the Company consists of the Board, the Board Risk
Management Committee (BRMC), the Executive Risk Committee (ERC) and its sub committees.
The risk philosophy of the Company is outlined in the Board approved risk policy which is
reviewed by the Board at least annually. The Board risk policy details identification,
measurement, monitoring and control standards relating to various individual risks, namely
investment (market, credit and liquidity), insurance, operational (including fraud, legal,
compliance, outsourcing, customer dissonance, business continuity, information and cyber
security) and reputation. The Board periodically reviews the potential impact of strategic
risks such as changes in macro-economic factors, government policies, regulatory
environment and tax regime on the business plan of the Company.
In addition to these risks, the life insurance industry faces a number of emerging
risks. Geo-political tensions and the potential for disruption to energy supplies are an
additional source of uncertainty for financial and commodity markets and a trigger for
inflation (which could impact credit quality of counterparties, as well as reduce real
wages thereby impacting discretionary savings, insurance new business and persistency
risk). There are also emerging risks related to ESG (environmental, social and governance)
issues. One of the most prominent ESG risks is that of climate change which could
potentially have wide-ranging implications including (but not limited to) adverse impact
on economic growth and investment markets and higher than expected claims due to increased
risk of future weather related catastrophes, pandemics as well as possible changes in
long-term mortality/morbidity rates. Apart from climate change, there are emerging risks
associated with public health trends such as increase in obesity related disorders and
demographic changes such as population urbanisation and ageing. Other important ESG
elements include data privacy which has an increasing material impact on Company's
reputation.
The risk management framework of the Company seeks to identify, measure and control its
exposures to all these risks within its overall risk appetite. The Company periodically
carries out stress testing of its assets and liabilities to identify impact on regulatory
and economic solvency, statutory profits and liquidity position. Such testing is used as
an aid in identifying significant existing or emerging risks to its financial position,
including the potential impact of severe economic shocks and catastrophic events like
pandemics, which could materialize as a consequence of several risk factors including
climate change and other sustainability risks. The Company has a framework for information
and cyber security as well as business continuity management to analyse emerging risks
through regular monitoring of the external and internal environment. The Company also has
a privacy policy to ensure protection of sensitive personal data or information collected.
The Company has updated the Board risk policy by integrating sustainability risks in the
risk management framework. The key aspects of the Company's risk management framework have
been outlined below. Further information on the Company's approach to risk management is
available in the sections on Enterprise Risk Management' and Risks and
Opportunities' of the Annual Report.
1.1. Investment risk
Investment risk is the risk arising out of variations in the level or volatility of
market prices of assets and financial instruments, including the risk arising from any
mismatch between assets and liabilities, due to external market and economic factors. The
Company faces limited liquidity risk due to the nature of its liabilities. The key
mitigation approaches for this risk are as follows:
(a) Product approval process: Launching new products or significant modifications to
existing products can significantly alter the risk profile of the Company's Balance Sheet.
Investment risks inherent in new products or significant modifications to existing
products are identified at product design stage and products are launched only after
approval by the ERC and the PMC.
(b) Asset Liability Management (ALM): The Company has detailed Investment
Specifications that govern the investment strategy and limits for each fund depending on
the profile of the liability backed by those assets. For each category of products, the
Investment Specifications define limits to permissible exposures to various asset classes,
duration guidelines for fixed income instruments and minimum investment in liquid assets.
The Company uses derivatives to hedge interest rate risk.
(c) Exposure limits have been defined for companies, groups and industries in
accordance with regulatory guidelines and the Company's internal Investment Policy. The
Company restricts investments primarily to securities rated AA and above.
(d) The Company has a liquidity contingency plan in place.
(e) As part of its ESG philosophy, the Company has implemented a framework for
investment decisions that will support mitigation of risks due to climate change as well
as other ESG risks by factoring these in its investment decisions.
1.2. Insurance Risk
Insurance risk is the risk arising because of variance to
the best estimate or because of random fluctuations in
the frequency, size and timing of insurance liabilities.
Insurance risk comprise the following components:
mortality, morbidity, persistency and expense risk.
These risks are mitigated through the following:
(a) Product approval process: Insurance risks inherent in the new products or
significant modifications to existing products are identified at product design stage and
products are launched only after approval by the ERC and the PMC. The Company, in its
product design, incorporates product features and uses appropriate policy wordings to
mitigate insurance risk.
(b) Reinsurance: The Company uses appropriate
reinsurance arrangements, including catastrophe reinsurance, to manage insurance risk.
Such reinsurance arrangements may be used to support risk transfer of sustainability risks
as well. The arrangements are with select and financially sound reinsurers. The Company's
reinsurance exposures are considered and approved by the ERC periodically.
(c) Underwriting and claims controls: Underwriting and claims policies and procedures
are in place to assess and manage mortality and morbidity risks. The Company seeks to
minimise these risks by diversifying its business portfolio and adhering to appropriate
and segmented underwriting norms. The Company conducts periodic reviews of both
underwriting and claims procedures. Adjustments to the underwriting strategy may be made
to allow for any changes in the insurance risk landscape or emerging risks.
(d) Experience analysis: The Company conducts its experience analysis regularly in
order to monitor trends, gain insights on emerging risks, if any and to ensure that
corrective actions can be initiated at the earliest opportunity and that assumptions used
in product pricing, reserving and embedded value reporting are in line with the
experience. The Company actively monitors its claims experience, persistency levels and
expense ratios.
(e) Aligning key performance indicators: The Company uses appropriate key performance
indicators for different levels of hierarchy in sales and operations to align interests
and ensure adequate focus on insurance risk especially, persistency and expense.
(f) Product contracts: The Company designs exclusions and terms and conditions in
consultation with reinsurers and with due regard to market practices to manage insurance
risk, especially mortality and morbidity risk. In order to deal with a changing insurance
landscape or emerging risks, new products may be developed with more suitable product
features, policy wordings, exclusions and terms and conditions.
(g) Repricing: The Company reserves the right to re-price future new business in case
of adverse experience, which could materialize due to various factors including
sustainability issues.
1.3. Operational risk:
Operational risk is the risk of loss, resulting from inadequate or failed internal
processes, people and systems, or from external events.
The Company uses the following approaches to manage operational risk:
(a) The Company develops and monitors mitigation plans for high-risk items identified
through the Risk and Control Self-Assessment (R&CSA) conducted for each business
function, through analysis of loss events and review of audit findings.
(b) The Company continuously monitors internal loss events and ensures adequate
mitigation for material impact events.
(c) The Company actively promotes a risk awareness culture by improving understanding
through communication and education. It further engages with law enforcement agencies to
create awareness on various insurance frauds and emerging issues.
(d) Fraud Management: The Company has a fraud risk management policy that sets out the
approach and guidelines for management of fraud risk. The Company follows both a proactive
and reactive approach to manage fraud. Proactive management is done by using triggers to
identify suspected frauds and through random sample checks. Reactive management is done
through incident management. The Company ensures implementation of controls to prevent
recurrence of such incidents, financial recovery whenever applicable and disciplinary
action against involved employees in accordance with the Company's Code of Conduct. It
also initiates actions through law enforcement authorities based on severity of incidents.
(e) Outsourcing Risk: The Company has an outsourcing policy to ensure effective
oversight and adequate due diligence with regard to outsourcing of activities. The Company
outsources processes which are permitted based on the regulatory guidelines. The Company
carries out required due diligence for any new vendor empanelment and annual assessment of
outsourced vendors.
(f) Business Continuity Management (BCM): The Company has a BCM policy and framework to
ensure resilience and continuity of key products and services at a minimum acceptable
level. BCM covers systems and processes for management of business continuity risk. The
Company has business continuity and disaster recovery plans in place for critical
processes, which are being tested periodically. The Company has been accredited with the
ISO
22301:2019 certification for the business continuity management systems.
(g) Information and cyber security: The Company has an information and cyber security
policy and framework that ensures all information assets are safeguarded by establishing
comprehensive management processes throughout the organisation. The Company has
defence-in-depth approach, and has deployed security solutions like firewalls, intrusion
prevention systems, anti-malware solutions, end-point detection and response (EDR), email
security, data leakage prevention, network access control (NAC) and web proxy.
Vulnerability assessment and penetration testing program for critical information
technology applications and infrastructure has been defined, to ensure IT Systems are
secured for operations during its life cycle. Further, cloud security strategy, practices
and advance level controls for protecting data and IT infrastructure has been implemented.
Cyber security operations centre (SOC) has been setup for proactive monitoring (24x7),
incident response, recovery and remediation activities. An awareness programme aimed at
educating users on best practices is in place, for protecting sensitive data and systems,
covering aspects related to cybersecurity, data security, business continuity and privacy.
Cyber security advisories issued by security experts are being monitored and suitable
actions are being initiated. Based on the Information Security Management System (ISMS)
controls implemented and the assessment conducted by the certification body, the Company
has been awarded a certification under ISO 27001:2022 standard.
(h) Privacy policy: The Company has a privacy policy in place which provides commitment
to privacy throughout the life cycle of the information from, collection, processing,
sharing, retention and destruction, by taking reasonable steps to protect the
confidentiality of the Personal Information provided and protect it from unauthorised
access or alteration, disclosure or destruction.
(i) The Company has adopted highest business, governance, ethical and legal standards.
The Whistle blower policy aims to provide a mechanism to ensure that concerns are
appropriately raised, independently investigated and addressed.
1.4. Reputation Risk:
Reputation risk is defined as the risk of negative opinion about the financial
stability, service levels, integrity, transparency or any other aspect, as perceived by
the stakeholders, resulting in a decline in business volumes and eventually impacting
continuity of business. The Company has a framework in place for managing reputation risk
and periodically monitors various parameters that could impact the reputation of the
Company.
Code of conduct under Securities and Exchange Board of India (Prohibition of Insider
Trading) Regulations, 2015
The Company has in place a Code of conduct to regulate, monitor and report trades in
Securities by Designated Persons (Code) which is in accordance with the SEBI
(Prohibition of Insider Trading) Regulations, 2015 as amended from time to time. The
objective of the Code is to achieve compliance with the SEBI (Prohibition of Insider
Trading) Regulations, 2015. Any infractions/ violations of the Code are suitably dealt
with as provided for in the Code.
CEO/CFO certification
In terms of the Listing Regulations, the certificate by the Managing Director & CEO
and Chief Financial Officer on the financial statements and internal controls relating to
financial reporting has been obtained.
CORPORATE GOVERNANCE
The Company considers its stakeholders as partners in success and remains committed to
delivering value to stakeholders. The Company believes that a sound corporate governance
mechanism is critical to retain and enhance stakeholders' trust. It is committed to
exercise overall responsibilities rigorously and diligently throughout the organisation,
managing its affairs in a manner consistent with corporate governance requirements and
expectations.
The Company's corporate governance philosophy is based on an effective independent
Board including the separation of Board's supervisory role from the executive management.
The Board Committees are generally comprising of a majority of independent/non-executive
Directors and are chaired by independent Directors, to oversee critical areas of business
operations.
Significant and material orders passed by the regulators or courts or tribunals
impacting the going concern status of the Company and its future operations
There are no significant and/or material orders passed by the regulators or courts or
tribunals impacting the going concern status of future operations of the Company.
Compliance to Secretarial Standards
The Company was in compliance with the applicable Secretarial Standards issued by the
Institute of Company Secretaries of India for FY2025.
Annual return
A copy of the annual return for FY2025 will be hosted on the website of the Company at https://www.iciciprulife.
com/about-us/shareholder-information/other.html
Particulars of employees
The statement containing the particulars of employees as required to be disclosed under
Section 197(12) of the CA2013, read with Rule 5(2) of the Companies (Appointment and
Remuneration of Managerial Personnel) Rules, 2014, forms part of this Report. In terms of
Section 136(1) of CA2013, the Report and the Accounts are sent to the members excluding
the aforesaid Annexure. Any member interested in obtaining a copy of this Annexure may
write to the Company Secretary at the Registered Office of the Company.
Corporate Social Responsibility (CSR) initiatives
The Corporate Social Responsibility policy as approved by the Board has been hosted on
the Company's website (https:// www.iciciprulife.com/about-us/corporate-policies.html).
In accordance with the provisions of Section 135 of the CA2013, and considering the
applicable dividend exemptions, the Company was not required to allocate any funds towards
CSR activities for FY2025. Notwithstanding this exemption, the Company, in alignment with
its values and commitment to social responsibility, voluntarily spent ' 25.1 million on
CSR initiatives during FY2025.
The detailed annual report on Corporate Social Responsibility activities is annexed
herewith as Annexure C.
Disclosures as per the Sexual Harassment of Women at Workplace (Prevention, Prohibition
and Redressal) Act, 2013
The Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal)
Act, 2013 provides protection against sexual harassment of women at the workplace and lays
down guidelines for the prevention and redressal of complaints of sexual harassment. The
Company has implemented its policy on prevention of sexual harassment at the workplace and
has made it available to all employees on the Company's intranet. The Company in its
endeavor to extending a safe and secure working environment, on an ongoing basis, ensures
awareness and sensitization of the policy amongst its employees.
Disclosures in relation to the Sexual Harassment of Women at Workplace (Prevention,
Prohibition and Redressal) Act, 2013:
a. number of complaints filed during the financial year: 21
b. number of complaints disposed of during the financial year: 21
c. number of complaints pending to be resolved as on end of financial year: NIL
Further, the Company has complied with provisions relating to the constitution of
Internal Committee under the Sexual Harassment of Women at Workplace (Prevention,
Prohibition and Redressal) Act, 2013.
Whistle blower policy
The Company has adopted highest business, governance, ethical and legal standards. The
Whistle Blower policy aims to provide a mechanism to ensure that concerns are
appropriately raised, independently investigated and addressed.
The purpose of the Policy is to encourage employees/ stakeholders to report matters
without the risk of subsequent victimisation, discrimination or disadvantage.
The Whistle Blower Policy covers all employees, including Directors of the Company and
stakeholders. The Policy encourages any employee, stakeholder or Director to report any
breach of any law, statute or regulation, issues related to accounting policies and
procedures, acts resulting in financial loss or loss of reputation, misuse of office,
suspected/actual fraud and criminal offences, non-compliance to anti-bribery and
anti-corruption policy. Besides, it also includes leak of any unpublished price sensitive
information (UPSI) pursuant to SEBI Regulations or any such information prescribed
pursuant to any regulations/laws, as amended from time to time. Such complaints are
reported to the Audit Committee of the Board.
The Policy has been periodically communicated to the employees and for stakeholders, an
extract of the same has also been hosted on the Company's intranet. The Whistle Blower
Policy complies with the requirements of vigil mechanism as stipulated under Section 177
of the Companies Act, 2013 and other applicable laws, rules and regulations. The details
of establishment of the Whistle Blower Policy are hosted on the website at https://www.iciciprulife.com/about-us/corporate-policies.
html?ID=about-corp.
Code of conduct
The Company has a code of conduct (Code) for Directors and employees of the Company,
which was last reviewed and amended by the Board of Directors at its meeting held on July
23, 2024. The Code aims at ensuring consistent standards of conduct and ethical business
practices across the constituents of the Company. The Code lays down the broad framework
of general guiding principles for conducting day-to-day business. This Code is available
on the website of the Company (https://
www.iciciprulife.com/about-us/corporate-policies.html). Pursuant to the Listing
Regulations, a confirmation from the Managing Director & CEO regarding compliance with
the Code by all the Directors and senior management forms part of this Annual Report.
Policy for determining material subsidiaries
In accordance with the requirements of the Listing Regulations, the Company has
formulated a policy for determining material subsidiaries and the same has been hosted on
the website of the Company (https://
www.iciciprulife.com/about-us/corporate-policies.html).
Board of Directors
The Company's Board is constituted in compliance with the CA2013, in accordance with
Listing Regulations,
IRDAI (Corporate Governance for Insurers) Regulations, 2024 and Master Circular on
Corporate Governance for Insurers, 2024.
At March 31, 2025, the Board of Directors of the Company comprised six independent
Directors, three non-executive non-independent Directors and the Managing Director &
CEO. Out of the three non-executive non-independent Directors, two Directors represents
ICICI Bank Limited and one Director represents Prudential Corporation Holdings Limited. As
at March 31, 2025, the Chairman of the Board is a non-executive non-independent Director.
Except the Managing Director & CEO, all other Directors including the Chairman of the
Board are non-executive Directors and/or independent Directors. The Board is responsible
for the corporate strategy and other responsibilities as laid down by IRDAI under the
IRDAI (Corporate Governance for Insurers) Regulations, 2024. The Managing Director &
CEO oversees implementation of the strategy, achievement of the business plan and
day-to-day operations. There is an appropriate mix of executive, non-executive and
independent Directors on various Board Committees. None of the Directors is/are related to
any other Director of the Company.
The Board functions either as a full Board or through various Committees constituted to
oversee specific areas. The Board has constituted Committees, namely, Board Audit
Committee, Board Risk Management Committee, Board Investment Committee, Board Policyholder
Protection, Grievance Redressal and Claims Monitoring Committee, Board Nomination and
Remuneration Committee, Board Sustainability and Corporate Social Responsibility
Committee, Stakeholders Relationship Committee, Board Information Technology Strategy
Committee and With Profits Committee.
The Company recognises that a diverse Board will have different thoughts, perspectives,
knowledge, skill, industry experience, age and gender, which will ensure that the Company
retains its competitive advantage. The Board Nomination and Remuneration Committee
recommends the appointment of Director(s) to the Board of the Company based on the
criteria for appointment of Directors.
In accordance with the Criteria for appointment of the Directors and those in
senior management positions that is who may be appointed as key managerial person/
personnel (KMP) or as senior managerial personnel (SMP)', identified by the Board, the
areas of qualification and positive attributes which would be required to be possessed by
the Board of the Directors of the Company in the context of life insurance business,
included finance & accountancy, banking, insurance, strategy and corporate planning,
risk management, securities market, economics, law and governance, consumer insights,
marketing and human resources. The Directors of the Company have the skills and expertise
as prescribed in the criteria, details of which are given below along with their
educational qualification, as at March 31, 2025.
Name of the Director |
Directors Identification Number (DIN) |
Educational Qualification |
Field of specialisation/ areas of core expertise |
Non-executive non-independent Directors |
|
|
|
Mr. Sandeep Batra, Chairman non-executive Director representing ICICI
Bank Limited 1 |
03620913 |
Chartered Accountant and Company Secretary |
Accountancy, Banking, Finance, Law, Information Technology, Human
Resources, Risk Management, Business Management, Insurance, Securities, Governance,
Economics |
Mr. Anuj Bhargava, non-executive Director representing |
02647635 |
Chartered Accountant from the Institute of Chartered Accountants of
India, Bachelor of Commerce (Sydenham College). |
Finance & accountancy, Banking, Strategy and Corporate planning |
ICICI Bank Limited |
|
|
|
Mr. Solmaz Altin, non-executive Director representing Prudential
Corporation Holdings Limited |
08206960 |
Graduate Degree in Banking and Economics (Diplom-Okonom), University of
Duisburg-Essen |
Insurance (life, health and non-life), corporate strategy and finance,
global transformation, digital and technology, customer centricity |
Non-executive independent Directors |
|
|
|
Mr. Dilip Karnik2 |
06419513 |
Bachelor's degree in Science and Bachelor's degree in Law (Gold
Medalist) |
Law and governance |
Mr. R. K. Nair |
07225354 |
Master's degree in Science, Bachelor's degree in Law, Master of Business
Administration - Financial Management, Diploma in Securities Law |
Finance & accountancy, banking, insurance, securities and economics,
law, human resources, risk management, information technology |
Ms. Vibha Paul Rishi |
05180796 |
Master of Business Administration in Marketing from the Faculty of
Management Studies, University of Delhi and Honours in Economics from Lady Sri Ram
College, Delhi University |
Consumer insights, marketing, human resources, strategy, corporate
planning, Finance & accountancy, agriculture and rural economy, information
technology, economics and risk management |
Mr. Naved Masood |
02126497 |
B. Sc (Hons), LLB (Hons) |
Securities, law and governance, risk management, Corporate Regulations,
Business Management and Public Policy |
Mr. Suresh Vaswani3 |
02176528 |
Management degree from Indian Institute of Management (IIM) Ahmedabad
and an engineering degree from Indian Institute of Technology (IIT) Kharagpur. |
Information technology, Investments, Business Management, strategy and
corporate planning, Merger & Acquisitions |
Ms. Anuradha Bhatia4 |
07278138 |
Master's degree in political science and a Bachelor's degree in law from
Delhi University |
Law and governance, Finance & accountancy, Taxation, Business
Management |
Whole-time Director(s) |
|
|
|
Mr. Anup Bagchi, Managing Director and Chief Executive Officer |
00105962 |
Management degree from Indian Institute of Management, Bangalore and
Engineering degree from Indian Institute of Technology, Kanpur |
Finance & accountancy, securities markets, insurance, banking,
strategy and corporate planning |
1
Mr. Sandeep Batra, a Non-Executive Director of the Company is re-designated and
appointed as Chairman of the Board of Directors, with effect from June 30, 2024.
2
Mr. Dilip Karnik ceased to be a Non-Executive Independent Director of the
Company with effect from May 10, 2025
3
Mr. Suresh Vaswani appointed as an Independent Director of the Company with
effect from July 4, 2024.
4
Ms. Anuradha Bhatia appointed as an Independent Director of the Company with
effect from March 12, 2025
During the year ended March 31, 2025, based on the recommendation of the Board
Nomination and Remuneration Committee, the Board of Directors of the Company considered
the following changes in the Board composition:
1. Retirement of Mr. M S Ramachandran (DIN: 00943629) as a non-executive Independent
Director and Chairman of the Board of Directors with effect from June 30, 2024, through
resolution dated March 15, 2024.
2. Re-designation and appointment of Mr. Sandeep Batra (DIN: 03620913), as Chairman of
the Board of Directors, with effect from June 30, 2024, through resolution dated March 15,
2024.
3. Appointment of Mr. Suresh Vaswani (DIN: 02176528) as an Additional (Independent)
Director of the Company, not liable to retire by rotation, with effect from July 4, 2024,
for a term of 5 (five) consecutive years commencing from July 4, 2024 till July 3, 2029,
vide resolution dated July 4, 2024.
4. Completion of tenure of Mr. Dileep Choksi (DIN: 00016322) as a non-executive
Independent Director of the Company with effect from December 26, 2024.
5. Appointment of Ms. Anuradha Bhatia (DIN: 07278138) as an Additional (Independent)
Director of the Company, not liable to retire by rotation, with effect from March 12,
2025, for a term of 5 (five) consecutive years commencing from March 12, 2025 till March
11, 2030, vide resolution dated March 12, 2025.
Accordingly, the Board had recommended the above appointments for approval of members
of the Company to transact the following special businesses:
1. Appointment of Mr. Suresh Vaswani (DIN: 02176528) as a non-executive Independent
Director of the Company, with effect from July 4, 2024, for a term of 5 (five) consecutive
years commencing from July 4, 2024 till July 3, 2029, by way of a Special resolution,
passed through postal ballot; and
2. Appointment of Ms. Anuradha Bhatia (DIN: 07278138) as a non-executive Independent
Director of the Company, with effect from March 12, 2025, for a term of 5 (five)
consecutive years commencing from March 12, 2025 till March 11, 2030, by way of a Special
resolution, passed through postal ballot
All the above resolutions were passed by the members, with requisite majority.
There were six meetings of the Board held during FY2025: Meetings were held on April
23, 2024, May 15, 2024, July 23,
2024, October 22, 2024, January 21, 2025 and March 12, 2025. The maximum interval
between any two meetings did not exceed 120 days. The attendance of Directors at the Board
meetings during the year is set out in the following table:
Name of the Director |
Board meetings attended/held during the year ended March 31, 2025 |
Attendance at last AGM (June 28, 2024) |
Non-executive non-independent Directors |
|
|
Mr. Sandeep Batra, Chairman, Non-executive Director representing ICICI
Bank Limited1 |
6/6 |
Present |
Mr. Anuj Bhargava, Non-executive Director representing ICICI Bank
Limited |
6/6 |
Present |
Mr. Solmaz Altin, Non-executive Director representing Prudential
Corporation Holdings Limited |
4/6 |
Present |
Non-executive independent Directors |
|
|
Mr. M. S. Ramachandran2 |
2/2 |
Present |
Mr. Dilip Karnik |
6/6 |
Present |
Mr. R. K. Nair |
6/6 |
Present |
Mr. Dileep Choksi3 |
4/4 |
Present |
Ms. Vibha Paul Rishi |
6/6 |
Present |
Mr. Naved Masood |
6/6 |
Present |
Mr. Suresh Vaswani4 |
4/4 |
Not Applicable |
Ms. Anuradha Bhatia5 |
1/1 |
Not Applicable |
Whole-time Director(s) |
|
|
Mr. Anup Bagchi, Managing Director & CEO |
6/6 |
Present |
1
Re-designated and appointed as Chairman of Board of Directors w.e.f. June 30,
2024
2
Retired as a non-executive Independent Director and Chairman of the Board of
Directors w.e.f. June 30, 2024.
3
Completion of tenure as a non-executive Independent Director w.e.f. December
26, 2024.
4
Appointed as an Independent Director of the Company w.e.f. July 4, 2024
5Appointed
as an Independent Director of the Company w.e.f. March 12, 2025
Note: Mr. Dilip Karnik ceased to be non-executive Independent Director of the Company
w.e.f. May 10, 2025.
The details of other directorships/committee membership held by the Directors of the
Company as at March 31, 2025 are set out below:
|
Number of |
Number of other committee memberships3 (Audit
Committee and Stakeholders Relationship Committee of Indian public limited companies) |
Names of other listed entities where the person is a
director and category of directorship |
|
other dir |
ectorships |
Name of the Director |
Indian public
limited
companies1 |
other companies2 ors |
Non-executive non-independent Direct |
|
|
|
|
Mr. Sandeep Batra, |
4(2) |
- |
3 |
1. ICICI Bank Limited, |
non-executive Director representing |
|
|
|
Executive Director |
ICICI Bank Limited |
|
|
|
2. ICICI Lombard General Insurance Company Limited,
Non-Executive - Non Independent Director |
|
Mr. Anuj Bhargava, non-executive Director representing ICICI Bank
Limited |
|
1 |
|
|
Mr. Solmaz Altin, non-executive Director representing Prudential
Corporation Holdings Limited |
|
4 |
|
|
Non-executive independent Directors |
|
|
|
|
Mr. Dilip Karnik |
2 |
|
1 |
1. Birla Corporation Limited, Non-Executive - Non Independent Director |
Mr. R. K. Nair |
5 |
4 |
6(3) |
1. ICICI Bank Limited, Non-Executive - Independent Director |
|
|
|
|
2. Geojit Financial Services Limited, Non-Executive - Independent
Director |
|
|
|
|
3. ICICI Securities Primary Dealership Limited (Debt
listed), Independent Director |
|
|
|
|
4. Inditrade Capital Limited, Non-Executive -
Independent Director |
Ms. Vibha Paul Rishi |
2 |
- |
2(2) |
1. ICICI Bank Limited, Non-Executive - Independent Director |
|
|
|
|
2. Piramal Pharma Limited, Non-Executive - Independent
Director |
Mr. Naved Masood |
1 |
- |
- |
- |
Mr. Suresh Vaswani |
2 |
7 |
3 |
1. Vodafone Idea Limited, Non-Executive - Independent Director |
|
|
|
|
2. Mastek Limited, Non-Executive - Independent Director |
Ms. Anuradha Bhatia |
- |
- |
- |
- |
Whole-time Director(s) |
|
|
|
|
Mr. Anup Bagchi, Managing Director & CEO |
2 |
|
|
|
Comprises of other public limited companies incorporated in India. Figures in
parentheses indicate Board chairpersonship by the Directors in other unlisted public
companies.
2
Comprises of private limited companies incorporated in India and foreign
companies but excludes Section 8 companies and not for profit foreign companies. Figures
in parentheses indicate Board chairpersonship.
3
Figures in parentheses indicate committee chairmanship including alternate
chairpersonship.
In terms of the Listing Regulations, the number of Committees (Audit Committee and
Stakeholders Relationship Committee) of public limited companies in which a Director is a
member/chairperson were within the limits prescribed under Listing Regulations, for all
the Directors of the Company. The number of directorships of each independent Director is
also within the limits prescribed under Listing Regulations.
Independent Directors
The Board of Directors of the Company at March 31, 2025 comprised of ten Directors, out
of which six are independent Directors.
All independent Directors have confirmed that they meet the criteria of independence as
laid down under Section 149(6) of the CA2013 and the Listing Regulations and have
confirmed that their names have been added in the data bank maintained by the Indian
Institute of Corporate Affairs for independent directors, in accordance with Rule 6 of the
Companies (Appointment and Qualification of Directors) Rules, 2014.
Pursuant to the provisions of Rule 6 of the Companies (Appointment and Qualifications
of Directors) Rules, 2014, every individual whose name is so included in the data bank
shall pass an online proficiency self-assessment test. However, an individual who has
fulfilled the criteria prescribed in Rule 6(4) of the said Rules, is exempt from passing
the online self-assessment test. In view of the same, none of the Independent Directors
were required to take the proficiency self-assessment test. The Board at its meeting held
on April 15, 2025, has reviewed the submissions received from all the independent
Directors and has confirmed that the independent Directors fulfil the criteria laid down
by requisite regulations and are independent from the management. Further, based on these
disclosures and confirmations, the Board is of the opinion that the Directors of the
Company are eminent persons with integrity and have necessary expertise and experience to
continue to discharge their responsibilities as the Director of the Company.
BOARD COMMITTEES
The details of Board Committees are as follows:
A. Board Audit Committee
The primary objective of the Committee is to monitor and provide an effective
supervision of the financial reporting process, with high levels of transparency,
integrity and quality of financial reporting. The Committee oversees the functions of
internal audit & compliance functions and ensures deployment of policies for an
effective control mechanism including mechanism to address potential conflict of interest
amongst stakeholders. The Committee has the authority and responsibility to select,
evaluate and recommend the statutory auditors in accordance with law. The Committee
ensures independence of control functions demonstrated by a credible reporting
arrangement.
Terms of reference:
i. Accounts & Audit
i. Oversee the financial statements, financial reporting process, statement of cash
flow and disclosure of its financial information, both on an annual and quarterly basis,
to ensure that the financial statement is correct, sufficient and credible;
ii. Recommend the appointment, re-appointment, terms of appointment and, if required,
the replacement or removal; remuneration, reviewing (with management) performance and
oversight of the work of the auditors (internal/ statutory/ concurrent/ Secretarial /
Forensic / Systems Audit) and to review and monitor the auditor's independence and
performance, and effectiveness of audit process;
iii. Oversight of the procedures and processes established to attend issues relating to
maintenance of books of account, administration procedures, transactions and other matters
having a bearing on the financial position of the Company, whether raised by the auditors
or by any other person;
iv. Evaluation of internal financial controls and risk management systems;
v. Discuss with the statutory auditors before the audit commences, about the nature and
scope of audit, as well as, have post-audit discussions to address areas of concern;
vi. To oversee the overall management costs of the insurer in compliance with the
limits prescribed by the Insurance Regulatory and Development Authority of India (IRDAI),
with the objective of protecting the interests of the policyholders;
vii. Approval of any additional work, other than statutory / internal audit, to the
statutory auditors or any of their associated persons or companies, with due consideration
for maintaining the independence and integrity of the audit relationship, ensuring
necessary disclosure related to such work entrusted to the auditor or its associates in
the Notes to Accounts forming part of the annual accounts of the insurer;
viii. Reviewing, with the management, the annual financial statements and auditor's
report thereon before submission to the Board for approval, with particular reference to:
Matters required to be included in the director's responsibility
statement to be included in the Board's report in terms of clause (c) of sub-section
(3) of Section 134 of the Companies Act, 2013;
Changes, if any, in accounting policies and practices and reasons for the same;
Major accounting entries involving estimates based on the exercise of judgment
by management;
Significant adjustments made in the financial statements arising out of audit
findings;
Compliance with listing and other legal requirements relating to financial
statements to the extent applicable;
Approval or any subsequent modification and disclosure of any related party
transactions of the Company, in accordance with applicable provisions, as amended from
time to time; and
Modified opinion(s) in the draft audit report.
ix. Reviewing, with the management, the quarterly, half-yearly and annual financial
statements before submission to the Board for approval;
x. To the extent applicable, review with the management, the statement of uses/ end
use/application of funds raised through an issue (public issue, rights issue, preferential
issue, etc.) and related matter, the statement of funds utilised for purposes other than
those stated in the offer document/ prospectus/ notice and the report submitted by the
monitoring agency monitoring the utilisation of proceeds of a public or rights issue, and
making appropriate recommendations to the Board to take up steps in this matter;
xi. Review of housekeeping items, particularly review of suspense balances,
reconciliations (including subsidiary general ledger (SGL) accounts) and other outstanding
assets & liabilities;
xii. Scrutiny of inter-corporate loans and investments, if any;
xiii. Valuation of undertakings or assets of the Company, wherever it is necessary;
xiv. To review the utilisation of loans and/ or advances from/investment by the holding
company in the subsidiary exceeding
' 100 crore or 10% of the asset size of the subsidiary, whichever is lower including
existing loans/advances/investments.
ii. Internal audit
i. Review the adequacy of internal audit function, if any, including the structure of
the internal audit department, staffing and seniority of the official heading the
department, reporting structure, coverage and frequency of internal audit;
ii. Oversee the efficient functioning of the internal audit department and review its
reports. The Committee would additionally monitor the progress made in rectification of
irregularities and changes in processes wherever deficiencies have come to notice;
iii. Set-up procedures and processes to address all concerns relating to adequacy of
checks and control mechanisms;
iv. Discussion with internal auditors of any significant findings and follow up there
on;
v. Review the findings of any internal investigations by the internal auditors into
matters where there is suspected fraud or irregularity or a failure of internal control
systems of a material nature and reporting the matter to the Board;
vi. Review with the management, performance of internal auditors and the adequacy of
the internal control systems;
vii. Look into the reasons for substantial defaults in the payment, if any, to the
depositors, debenture holders, shareholders (in case of non-payment of declared dividends)
and creditors; and
viii. Review the functioning of the whistle blower/vigil mechanism.
iii. Compliance & ethics and others
i. Monitor the compliance function and the Company's risk profile in respect of
compliance with external laws and regulations and internal policies, including the
Company's code of ethics or conduct;
ii. Review reports on the above and on proactive compliance activities aimed at
increasing the Company's ability to meet its legal and ethical obligations, on identified
weaknesses, lapses, breaches or violations and the controls and other measures in place to
help detect and address the same;
iii. Discuss the level of compliance in the Company and any associated risks and to
monitor and report to the Board on any significant compliance breaches;
iv. Supervise and monitor matters reported using the Company's whistle blowing or other
confidential mechanisms for employees and others to report ethical and compliance concerns
or potential breaches or violations;
v. Advise the Board on the effect of the above on the Company's conduct of business and
helping the Board set the correct tone at the top' by communicating, or supporting
the communication, throughout the Company of the importance of ethics and compliance;
vi. Approve compliance programmes, reviewing their effectiveness on a regular basis and
signing off on any material compliance issues or matters;
vii. Review key transactions involving conflict of interest;
viii. Review the anti-money laundering (AML)/ counter - financing of terrorism (CFT)
policy annually and review the implementation of the Company's AML/CFT program;
ix. Review compliance of Insurance Regulatory & Development Authority of India
(IRDAI) corporate governance guidelines;
x. Monitor the directives issued/ penalties imposed/ penal action taken against the
Company under various laws and statutes and action taken for corrective measures; and
xi. Approval of appointment of chief financial officer or any other person heading the
finance function or discharging that function after assessing the qualifications,
experience and background, etc. of the candidate.
xii. Consider and comment on rationale, cost-benefits and impact of schemes involving
merger, demerger, amalgamation etc., on the Company and its shareholders.
xiii. Carrying out any other function, if any, as is mentioned in the terms of
reference of the Board Audit Committee and any other terms of reference as may be decided
by the Board and/or specified/ provided under the Companies Act, 2013 or the Securities
and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations,
2015, or the IRDAI (Corporate Governance for Insurers) Regulations, 2024 read with Master
Circular on Corporate Governance for Insurers, 2024 or by any other regulatory authority.
Composition
There were ten meetings of the Board Audit Committee held during FY2025: Meetings were
held on April 22, 2024, April 23, 2024, June 24, 2024, July 22, 2024, July 23, 2024,
October 21, 2024, October 22, 2024, January 20, 2025, January 21, 2025, February 17, 2025.
The details of the composition of the Committee and attendance at its meetings are set out
in the following table:
Name of the member |
Number of meetings attended/ held |
Mr. R. K. Nair - Chairman |
10/10 |
Mr. Dileep Choksi1 |
7/7 |
Mr. Dilip Karnik |
10/10 |
Ms. Vibha Paul Rishi |
10/10 |
Mr. Suresh Vaswani2 |
7/7 |
Ms. Anuradha Bhatia3 |
0/0 |
Mr. Sandeep Batra4 |
3/3 |
Mr. Anuj Bhargava5 |
6/7* |
Mr. Solmaz Altin |
5/10 |
1
Ceased to be a member w.e.f. December 26, 2024
2
Appointed as member w.e.f. July 4, 2024
3
Appointed as member w.e.f. March 13, 2025
4
Ceased to be a member w.e.f. June 30, 2024
5
Appointed as member w.e.f. June 30, 2024
* Mr. Anuj Bhargava attended the Board Audit Committee meeting held on April 23, 2024,
as an invitee Note: Mr. Dilip Karnik ceased to be a member of the Committee w.e.f. May 10,
2025
B. Board Risk Management Committee
The Committee reviews the Risk Management policy of the Company, including asset
liability management (ALM), to monitor all risks across the various lines of business of
the Company and establish appropriate systems to mitigate such risks. The Committee also
reviews the risk appetite and risk profile of the Company. The Committee oversees the
effective operation of the risk management system and advises the Board on key risk
issues.
Terms of reference:
a. Risk management
i. Establish effective Risk Management framework for identification of internal and
external risks, in particular including financial, operational, sectoral, sustainability
(particularly ESG related risks), information and cyber security risks, business
continuity risk or any other risk as may be determined by the Committee and recommend to
the Board the Risk Management Policy and processes for the organisation which should
include measures for risk mitigation including systems and processes for internal control
of identified risks;
ii. Monitor and oversee implementation of the Risk Management Policy, including
evaluating the adequacy of risk management systems;
iii. Ensure that appropriate methodology, processes and systems are in place to monitor
and evaluate risks associated with the business of the Company;
iv. Set the risk tolerance limits and assess the cost and benefits associated with risk
exposure;
v. Review the Company's risk-reward performance to align with overall policy
objectives;
vi. Discuss and consider best practices in risk management in the market and advise the
respective functions;
vii. Assist the Board in effective operation of the risk management system by
performing specialised analyses and quality reviews;
viii. Maintain an aggregated view on the risk profile of the Company for all categories
of risk including insurance risk, market risk, credit risk, liquidity risk, operational
risk, compliance risk, legal risk, reputation risk, etc.;
ix. Advise the Board with regard to risk management decisions in relation to strategic
and operational matters such as corporate strategy, acquisitions and related matters;
x. Report to the Board, the nature and content of its discussions, recommendations and
actions to be taken including details on the risk exposures and the actions taken to
manage the exposures, review, monitor and challenge where necessary, risks undertaken by
the Company;
xi. Review the solvency position of the Company on a regular basis;
xii. Monitor and review regular updates on business continuity;
xiii. Formulation of a Fraud monitoring policy and framework for approval by the Board;
xiv. Monitor implementation of Anti-fraud policy for effective deterrence, prevention
detection and mitigation of frauds;
xv. Review compliance with the guidelines on Insurance Fraud Monitoring Framework dated
January 21, 2013, issued by the Authority;
xvi. Monitor and review the cyber security practice;
xvii. Approve Business Continuity Plan (BCP) of the Company annually;
xviii. Review the appointment, removal and terms of remuneration of the Chief Risk
Officer;
xix. Effective oversight of Product Management Committee of the Company in line with
the provisions under the IRDAI (Insurance Products) Regulations, 2024; and to review any
deviations to Product Management & Pricing (PMP) policy and recommend
changes to the PMP policy or the controls put in place to implement the PMP policy
xx. Carry out any other function, if any, as prescribed in the terms of reference of
the BRMC and any other terms of reference as may be decided by the Board and/or
specified/provided under the Companies Act, 2013 or the Securities and Exchange Board of
India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, or
the IRDAI (Corporate Governance for Insurers) Regulations, 2024 read with Master Circular
on Corporate Governance for Insurers, 2024 or by any other regulatory authority.
b. Asset liability management (ALM)
i. Setting the risk/reward objectives i.e. risk appetite of the Company informed by
assessment of policyholder expectations and other relevant factors;
ii. Quantifying the level of risk exposures (e.g. market, credit and liquidity) and
assessing the expected rewards and costs associated with the risk exposure;
iii. Formulating and implementing optimal ALM strategies, both at the product level an
enterprise level;
iv. Ensuring that liabilities are backed by appropriate assets and manage mismatches
between assets and liabilities to ensure they remain within acceptable monitored
tolerances for liquidity, solvency and the risk profile of the Company;
v. Monitor risk exposures at periodic intervals and revising ALM strategies where
required;
vi. Reviewing, approving and monitoring systems, controls and reporting used to manage
balance sheet risks including any mitigation strategies;
vii. Ensuring that management and valuation of all assets and liabilities comply with
the standards, prevailing legislation and internal and external reporting requirements;
viii. Submitting the ALM information before the Board at periodic intervals. Annual
review of strategic asset allocation;
ix. Reviewing key methodologies and assumptions including actuarial assumptions, used
to value assets and liabilities;
x. Managing capital requirements at the company level using the regulatory solvency
requirements;
xi. Reviewing, approving and monitoring capital plans and related decisions over
capital transactions (e.g. dividend payments, acquisitions, disposals, etc.).
xii. Reviewing the reinvestment decisions of matured investments considering the
duration of liabilities.
xiii. Carrying out any other function, if any, as prescribed in the terms of reference
of the Board Risk Management Committee and any other terms of reference as may be decided
by the Board and/or specified/provided under the Companies Act, 2013 or the Securities and
Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations,
2015, as amended, or IRDAI (Corporate Governance for Insurers) Regulations, 2024 read with
Master Circular on Corporate Governance for Insurers, 2024 or by any other regulatory
authority.
Composition
There were four meetings of the Board Risk Management Committee held during FY2025: The
meetings were held on April 22, 2024, July 22, 2024, October 21, 2024 and January 20,
2025. The details of the composition of the Committee and attendance at its meetings are
set out in the following table:
Name of the member |
Number of meetings attended/ held |
Mr. Naved Masood - Chairman1 |
3/3 |
Mr. M. S. Ramachandran2 |
1/1 |
Mr. R. K. Nair |
4/4 |
Mr. Suresh Vaswani3 |
3/3 |
Mr. Anuj Bhargava4 |
1/1 |
Mr. Sandeep Batra5 |
3/3 |
Mr. Solmaz Altin |
2/4 |
Mr. Anup Bagchi6 |
3/3 |
Mr. Deepak Kinger6 |
3/3 |
Mr. Dhiren Salian6 |
3/3 |
Mr. Souvik Jash6 |
3/3 |
1
Appointed as a Chairman and member w.e.f. June 30, 2024
2
Ceased to be Chairman and member w.e.f. June 30, 2024
3
Appointed as a member w.e.f. July 4, 2024
4
Ceased to be a member w.e.f. June 30, 2024
5
Appointed as a member w.e.f. June 30, 2024
6
Appointed as a member w.e.f. June 30, 2024, pursuant to IRDAI (Corporate
Governance for Insurers) Regulations, 2024 read with the Master Circular on Corporate
Governance for Insurers, 2024 which states that the Risk
Management Committee shall also have the Chief Executive Officer, the Chief Financial
Officer, the Appointed Actuary and the Chief Risk Officer, as members. Further, they
attended the meeting held on April 22, 2024, as invitees
C. Board Investment Committee
The Investment Committee assists the Board in fulfilling its oversight responsibility
for the investment assets of the Company. The Committee is responsible for formulating the
overall investment policy and establishing a framework for its investment operations with
adequate controls. The Committee also monitors investment performance against the
applicable benchmarks and provide guidance for protection of shareholders' and
policyholders' funds.
Terms of reference:
i. Responsible for the recommendation of the Investment Policy and laying down of the
operational framework for the investment operations of the Company. The Investment Policy
and operational framework should, inter alia, encompass aspects concerning liquidity for
smooth operations, compliance with prudential regulatory norms on investments, risk
management/mitigation strategies to ensure commensurate yield on investments in line with
policyholders' reasonable expectations and above all protection of policyholders' funds.
ii. Put in place an effective reporting system to ensure compliance with the Investment
Policy set out by it apart from internal/concurrent audit mechanisms for a sustained and
on-going monitoring of investment operations.
iii. To submit a report to the Board on the performance of investments at least on a
quarterly basis and provide an analysis of its investment portfolio (including with regard
to the portfolio's safety and soundness) and on the future outlook.
iv. The Committee should independently review its investment decisions and ensure that
support by the internal due diligence process is an input in making appropriate investment
decisions.
v. To carry out any other function, if any, as prescribed in the terms of reference of
the Board Investment Committee and any other terms of reference as may be decided by the
Board and/or specified/provided under the CA2013 or the IRDAI (Corporate Governance for
Insurers) Regulations, 2024 read with Master Circular on Corporate Governance for
Insurers, 2024 or by any other regulatory authority.
Composition
There were five meetings of the Board Investment Committee held during FY2025: The
meetings were held on April 22, 2024, July 22, 2024, October 21, 2024, November 21, 2024,
and January 20, 2025.
The details of the composition of the Committee and attendance at its meetings are set
out in the following table:
Name of the member |
Number of meetings attended/ held |
Mr. Suresh Vaswani - |
4/4 |
Chairman1 |
|
Mr. M. S. Ramachandran2 |
1/1 |
Mr. R. K. Nair |
5/5 |
Mr. Sandeep Batra |
5/5 |
Mr. Solmaz Altin |
2/5 |
Mr. Anup Bagchi |
5/5 |
Mr. Dhiren Salian* |
5/5 |
Mr. Manish Kumar* |
5/5 |
Mr. Deepak Kinger* |
5/5 |
Mr. Souvik Jash* |
5/5 |
1
Appointed as Chairman and member w.e.f. July 4, 2024
2
Ceased to be the member and Chairman w.e.f. June 30, 2024 * Pursuant to IRDAI
(Corporate Governance for Insurers)
Regulations, 2024 read with Master Circular on Corporate Governance for Insurers, 2024,
the Board Investment Committee shall also have the Chief Financial Officer, Chief
Investment Officer, Chief Risk Officer and the Appointed Actuary, as members.
D. Board Policyholder Protection, Grievance Redressal and Claims Monitoring Committee
The Committee assists the Board to protect the interests of the policyholders and
improve their experiences in dealing with the Company at all stages and levels of their
relationship with the Company. In this connection, the Committee aims to upgrade and
monitor policies and procedures for grievance redressal and resolution of disputes,
disclosure of material information to the policy holders, and compliance with
the regulatory requirements.
Terms of reference:
i. Adopt standard operating procedures to treat the customer fairly including
time-frames for policy and claims servicing parameters and monitoring implementation
thereof;
ii. Establish effective mechanism to address complaints and grievances of policyholders
including mis-selling by intermediaries;
iii. Put in place a framework for review of awards given by Insurance
Ombudsman/Consumer Forums. Analyse the root cause of customer complaints, identify market
conduct issues and advise the management appropriately about rectifying systemic issues,
if any;
iv. Review all the awards given by Insurance Ombudsman/Consumer Forums remaining
unimplemented for more than Thirty (30) days with reasons thereof and report the same
to the Board for initiating remedial action, where necessary;
v. Review the measures and take steps to reduce complaints at periodic intervals;
vi. Ensure compliance with the statutory requirements as laid down in the regulatory
framework pertaining to policyholders' protection;
vii. Provide the details of grievances at periodic intervals in such formats as may be
prescribed by the Authority;
viii. Ensure details of insurance ombudsmen are provided to the policyholders;
ix. Review of claims report, including status of outstanding claims with ageing of
outstanding claims;
x. Reviewing repudiated claims with analysis of reasons;
xi. Status of settlement of other customer benefit payouts like surrenders, loan, and
partial withdrawal requests, etc; and
xii. Review the settlement of unclaimed amounts on a quarterly basis, including the
number and amounts of claims. Also, review the steps taken to reduce unclaimed amounts by
identifying policyholders or beneficiaries and creating awareness in accordance with the
Standard operating procedure/policy approved by the Committee.
xiii. Ensure that there is a Grievance Redressal officer in place who shall be
responsible for grievance redressal and whose details shall be made available at the
website.
xiv. Carrying out any other function, if any, as prescribed in the terms of reference
of the Board Policyholder Protection, Grievance Redressal and Claims Monitoring Committee
and any other terms of reference as may be decided by the Board and/or specified/provided
under IRDAI (Corporate Governance for Insurers) Regulations, 2024 read with Master
Circular on Corporate Governance for Insurers, 2024 or by any other regulatory authority.
The Grievance Redressal Committee (GRC) is chaired by Mr. Rajagopalan Venkatarama, an
eminent independent member. The other members of the Committee comprise of Ms. Poonam
Bharadwaj, an independent member and three other internal members. As part of the
grievance redressal mechanism, the GRC is constituted as the final authority to address
the policyholders' grievances before approaching the Regulator and the Ombudsman office. A
summary of the key discussions of the GRC meeting are placed at the
Board Policyholder Protection, Grievance Redressal and Claims Monitoring Committee for
information.
The GRC meets on a quarterly basis with the following terms of reference:
a. Evaluate feedback on quality of customer service and claims experience.
b. Review and approve representations received on claims repudiations and complaints.
c. Ensure that the Company follows all prescribed regulatory requirements on
policyholder service.
d. Submit report on its performance to the Board Policyholder Protection, Grievance
Redressal and Claims Monitoring Committee on a quarterly basis.
Composition
There were four meetings of the Board Policyholder Protection, Grievance Redressal and
Claims Monitoring Committee held during FY2025: Meetings were held on April 18, 2024, July
23, 2024, October 14, 2024 and January 21, 2025. The details of the composition of the
Committee and attendance at its meetings are set out in the following table:
Name of the member |
Number of meetings attended/ held |
Ms. Vibha Paul Rishi - |
4/4 |
Chairperson |
|
Mr. Dilip Karnik |
4/4 |
Mr. Dileep Choksi1 |
2/3 |
Mr. Naved Masood2 |
3/3 |
Mr. Anuj Bhargava |
4/4 |
Mr. Solmaz Altin |
2/4 |
1
Ceased to be a member w.e.f. December 26, 2024
2
Appointed as a member w.e.f. June 30, 2024
Note: Mr. Dilip Karnik ceased to be a member of the Committee w.e.f. May 10, 2025
Note: Mr. Rajagopalan Venkatarama, independent
customer representative attended the Committee meetings held on April 18, 2024, July
23, 2024, October 14, 2024 and January 21, 2025, as an invitee.
E. Board Nomination and Remuneration Committee
The Board Nomination and Remuneration Committee assists the Board to formulate policies
relating to the composition and remuneration of the Directors, key managerial personnel,
other employees consistent with criteria approved by the Board. The Committee coordinates
and oversee the self-evaluation of the performance of the Board and succession planning
for senior management. The Committee ensures that the Board comprises of competent and
qualified Directors.
Terms of reference:
i. To formulate the criteria for determining qualifications, positive attributes and
independence of a director;
ii. To devise a policy on diversity of the Board;
iii. To identify persons who are qualified to become directors and who may be appointed
in senior management in accordance with the criteria laid down, recommend to the Board
their appointment and removal and formulate a criteria and specify the manner for
effective evaluation of every individual director's performance, evaluation of the
performance of Board and its committees; and review its implementation and compliance;
iv. To scrutinise the declarations of intending applicants before the appointment/
re-appointment/ election of directors by the shareholders at the annual general meeting;
and to scrutinise the applications and details submitted by the aspirants for appointment
as the key managerial personnel/ key management persons (KMPs); and to make independent/
discreet references, where necessary, well in time to verify the accuracy of the
information furnished by the applicant;
v. To consider whether to extend or continue the term of appointment of the independent
director, on the basis of the report of performance evaluation of independent directors;
vi. To ensure that the proposed appointments/ re-appointments of KMPs or directors are
in conformity with the Board approved policy on retirement/ superannuation;
vii. To ensure that an annual declaration is obtained from the Directors/ KMPs that the
information provided in the declaration at the time of appointment/ reappointment has not
undergone any change subsequently and the changes, if any, are apprised by the concerned
Director to the Board;
viii. To determine and recommend to the Board a policy, relating to the remuneration
for the directors, the CEO, KMPs, and other employees, in alignment with applicable
guidelines and framework;
ix. To consider and approve employee stock option schemes and to administer and
supervise the same;
x. To recommend to the Board, all remuneration, in whatever form, payable to senior
management and ensure that the remuneration for KMPs is as per the Compensation Policy
approved by the Board;
xi. To ensure that the level and composition of remuneration is reasonable and
sufficient to attract, retain and motivate directors of the quality required to run the
Company successfully;
xii. To approve the compensation program and to ensure that remuneration to directors,
KMPs and senior management involves a balance between fixed and incentive pay reflecting
short and long term performance objectives appropriate to the working of the Company and
its goals;
xiii. To ensure that relationship of remuneration to performance is clear and meets
appropriate performance benchmarks;
xiv. To ensure the succession planning for the Directors and the KMPs of the Company
including its implementation.
xv. To carry out any other function, if any, as prescribed in the terms of reference of
the Board Nomination and Remuneration Committee and any other terms of reference as may be
decided by the Board and/or specified/provided under the Companies Act, 2013 or the
Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements)
Regulations, 2015, as amended, or the IRDAI (Corporate Governance for Insurers)
Regulations, 2024 read with Master Circular on Corporate Governance for Insurers, 2024 or
by any other regulatory authority.
Composition
There were five meetings of the Board Nomination and Remuneration Committee held during
FY2025: April 23, 2024, July 4, 2024, July 22, 2024, January 20, 2025, March 12, 2025. The
details of the composition of the Committee and attendance at its meetings are set out in
the following table:
Number of
Name of the member meetings attended/
held
Mr. Dilip Karnik - Chairman |
5/5 |
Mr. M. S. Ramachandran1 |
1/1 |
Mr. Dileep Choksi2 |
3/3 |
Ms. Vibha Paul Rishi |
5/5 |
Mr. R. K. Nair3 |
4/4 |
Mr. Naved Masood4 |
2/2 |
Ms. Anuradha Bhatia5 |
0/0 |
Mr. Sandeep Batra |
5/5 |
Mr. Solmaz Altin |
3/5 |
1
Ceased to be a member w.e.f. June 30, 2024
2
Ceased to be a member w.e.f. December 26, 2024
3
Appointed as a member w.e.f. June 30, 2024
4
Appointed as a member w.e.f. December 26, 2024
5
Appointed as a member w.e.f. March 13, 2025
Note: a) Mr. Dilip Karnik ceased to be a member and Chairman of the Committee w.e.f.
May 10, 2025, and b) Mr. R. K. Nair was appointed as the Chairman of the Committee w.e.f.
May 10, 2025
F. Board Sustainability and Corporate Social Responsibility Committee
The purpose of the Committee is to formulate and recommend to the Board the CSR policy
of the Company, formulate the annual CSR plan, and monitor the CSR activities and
compliance with the CSR policy from time to time. Corporate Social Responsibility Policy
of the Company as per section 135 of the CA2013 is put up on the Company's website.
Further, the Committee oversees and monitors the matters related to Sustainability
including Environment, Social and Governance (ESG) and Business Responsibility and
Sustainability initiatives undertaken by the Company.
Terms of reference:
i. To formulate and recommend to the Board, a Corporate Social Responsibility Policy
which shall indicate the activities to be undertaken by the Company;
ii. To recommend the amount of expenditure to be incurred on the Corporate Social
Responsibility activities;
iii. To monitor the Corporate Social Responsibility Policy of the Company from time to
time;
iv. To oversee and monitor Sustainability activities including ESG initiatives
undertaken by the Company, related key disclosures, review its performance thereon and
advice on related matters; and
v. To review and monitor matters related to Sustainability such as the ESG Report,
Business Responsibility and Sustainability Report.
Composition
There were two meetings of the Board Sustainability and Corporate Social Responsibility
Committee held during FY2025: Meeting were held on April 18, 2024, and October 22, 2024.
The details of the composition of the Committee and attendance at its meetings are set out
in the following table:
Name of the member |
Number of meetings attended/ held |
Mr. Dilip Karnik - Chairman |
2/2 |
Mr. Dileep Choksi1 |
1/2 |
Mr. Naved Masood2 |
1/1 |
Ms. Anuradha Bhatia3 |
0/0 |
Mr. Solmaz Altin |
2/2 |
1
Ceased to be a member w.e.f. December 26, 2024
2
Appointed as a member w.e.f. June 30, 2024
3
Appointed as a member w.e.f. March 13, 2025
Note: a) Mr. Dilip Karnik ceased to be a member and Chairman of the Committee w.e.f.
May 10, 2025, and b) Ms. Anuradha Bhatia was appointed as the Chairperson of the Committee
w.e.f. May 10, 2025
G. Stakeholders Relationship Committee Terms of reference:
i. Consider and review redressal and resolutions of the grievances and complaints of
the security holders of the company, including those of shareholders, debenture holders
and other security holders related to transfer/ transmission of shares, non-receipt of
annual report, non-receipt of declared dividends, issue of new/duplicate certificates,
general meetings;
ii. Approval and rejection of transfer and transmission of shares or securities,
including preference shares, bonds, debentures and securities;
iii. Approval and rejection of requests for split and consolidation of share
certificates;
iv. Approval and rejection of issue of duplicate share, issued from time to time;
v. Redemption of securities and the listing of securities on stock exchanges;
vi. Allotment of shares and securities;
vii. Review of measures taken for effective exercise of voting rights by shareholders;
viii. Review of adherence to the service standards adopted by the Company in respect of
various services being rendered by the Registrar & Share Transfer Agent;
ix. Review of various measures and initiatives taken by the Company for reducing the
quantum of unclaimed dividends and ensuring timely receipt of dividend warrants/annual
reports/statutory notices by the shareholders of the company; and
x. Any other activities which are incidental or ancillary to the various aspects of
interests of shareholders, debenture holders and/or other security holders.
Composition
There were four meetings of the Stakeholders Relationship Committee held during FY2025:
April 22, 2024, July 22, 2024, October 21, 2024 and January 20, 2025. The details of the
composition of the Committee and attendance at its meetings are set out in the following
table:
Name of the member |
Number of meetings attended/ held |
Mr. Naved Masood - |
3/3 |
Chairman1 |
|
Mr. Dileep Choksi2 |
3/3 |
Mr. R. K. Nair |
4/4 |
Mr. Anup Bagchi |
4/4 |
1
Appointed as a member w.e.f. June 30, 2024 and as Chairman of the Committee
w.e.f. December 26, 2024
2
Ceased to be a member w.e.f. December 26, 2024
Ms. Priya Nair, Company Secretary is designated as the Compliance Officer of the
Company in accordance with the requirements of the Listing Regulations. The total number
of complaint from shareholders in FY2025 was 1 pertaining to non-receipt of the Annual
report. The said complaint was addressed within the prescribed timeline. At March 31,
2025, no complaints were pending for resolution.
H. With Profits Committee Terms of reference:
i. Maintaining the asset shares;
ii. Providing approval for the detailed working of the asset share, the expense allowed
for in the asset share, the investment income earned on the fund, and other associated
elements which were represented in the asset share determined by the Appointed Actuary;
and
iii. To submit a report to the Board covering at least:
1. appropriateness of the methodology and basis used in calculation of asset shares and
justification for any change,
2. bonus earning capacity including its calculation,
3. sensitivity analysis of bonus rates and basis as appropriate,
4. a brief note on how policyholders' reasonable expectations (PRE) is met,
5. any change in special surrender value with justification,
6. treatment of With Profit fund for future appropriation (FFA) along with details on
reconciliation of opening FFA to closing FFA, and
7. the expenses debited to the With Profit fund and its appropriateness.
iv. To carry out any other function, if any, as prescribed in the terms of reference of
the With Profits Committee and any other terms of reference as may be decided by the Board
and/ or specified/provided under IRDAI (Corporate Governance for Insurers) Regulations,
2024 read with Master Circular on Corporate Governance for Insurers, 2024 or by any other
regulatory authority.
Composition
There was one meeting of the With Profits Committee held during FY2025: Meeting was
held on April 22, 2024. The details of the composition of the Committee and attendance at
its Meeting are set out in the following table:
Name of the member |
Number of meetings attended/held |
Mr. R. K. Nair - Chairman |
1/1 |
Mr. Sandeep Batra1 |
1/1 |
Mr. Solmaz Altin |
1/1 |
Mr. Anuj Bhargava2 |
0/0 |
Mr. Anup Bagchi |
1/1 |
Mr. Heerak Basu* |
1/1 |
Mr. Dhiren Salian* |
1/1 |
Mr. Souvik Jash* |
1/1 |
* Pursuant to IRDAI (Corporate Governance for Insurers) Regulations, 2024 read with
Master Circular on Corporate Governance for Insurers, 2024, With Profits Committee shall
also have the Chief Financial Officer, the Appointed Actuary and an Independent Actuary,
as members. 1Ceased to be a member w.e.f. June 30, 2024 2Appointed
as a member w.e.f. June 30, 2024
I. Information Technology Strategy Committee
Given the increased emphasis surrounding the rapidly evolving digital landscape
including enhanced cyber risk, the Board Information Technology Strategy Committee has
been constituted to provide oversight in the strategic aspects for leveraging technology
for the Company's business.
Terms of reference
i. To review IRDAI directives in the areas of information technology and cyber security
for necessary implementation;
ii. To approve Information Technology (IT) Strategy and Policy documents;
iii. To review IT risks;
iv. To review cyber risk;
v. To oversee performance of critical IT systems;
vi. To review key IT initiatives and its alignment with Business strategy;
vii. To oversee IT investments for sustaining the Company's growth and ascertaining the
availability of resources for managing IT risks; and
viii. To review Technology from a future readiness perspective.
Composition
There were four meetings of the Board Information Technology Strategy Committee held
during FY2025: April 11, 2024, August 20, 2024, November 11,
J.
2024 and February 17, 2025. The details of the composition of the Committee and
attendance at its Meeting are set out in the following table:
Name of the member |
Number of meetings attended/ held |
Mr. Suresh Vaswani - Chairman1 |
3/3 |
Mr. M. S. Ramachandran2 |
1/1 |
Ms. Vibha Paul Rishi |
4/4 |
Mr. Sandeep Batra |
4/4 |
Mr. Solmaz Altin |
2/4 |
Mr. Anup Bagchi |
4/4 |
1
Appointed as member and Chairman w.e.f. July 4, 2024
2
Ceased to be a member and Chairman w.e.f. June 30, 2024
Strategy Committee
The Board of Directors at its meeting held on January 19, 2018 had constituted a
Strategy Committee to consider and evaluate any combination, arrangement, transfer of
assets, acquisition, divestiture and any other strategic initiative and recommend such
proposals to the Board of Directors.
It was concurred by the Board of Directors that any such strategic initiative and
proposals, in the future, will be evaluated directly by the Board of Directors and hence
the said Committee was dissolved with effect from June 30, 2024.
Familiarisation programme for Independent Directors
Independent Directors are familiarised with their roles, rights and responsibilities in
the Company as well as with the nature of the industry and the business model of the
Company through induction programmes and regular updates as follows:
Induction Programme for new Appointee:
Induction programmes are organised for new Appointees, wherein an overview of the
Company, its vision and mission, the industry in which it operates, its business,
strategies, risk management, organisation structure and other areas of relevance is shared
with the Director. The Director is also briefed on the regulatory requirements and
disclosure norms. Each of functional heads of the Company brief the new Director on the
different aspects of the business as well as critical support functions of the Company.
Regular Updates
Presentations are made at quarterly Board Meetings on performance review, strategy and
key regulatory developments. An exclusive meeting of the Board of Directors to discuss and
approve the strategy of the Company is convened on an annual basis.
The details of the familiarisation programmes have been hosted on the website of the
Company and can be accessed on the link: https://www.iciciprulife.com/
about-us/company-overview/familiarization.html.
Changes in the composition of the Board of Directors and other key managerial personnel
(KMP) as per CA2013 during the year ended March 31, 2025
Name of Director/KMP |
Appointment/ Resignation/ Cessation of tenure/Retirement/
Superannuation/ Withdrawal of nomination |
With effect from |
Ms. Sonali Chandak |
Resigned as a Company Secretary |
May 21, 2024 |
Ms. Priya Nair |
Appointed as a Company Secretary |
May 21, 2024 |
Mr. M. S.
Ramachandran |
Retirement as Chairman and nonexecutive Independent Director |
June 30, 2024 |
Mr. Suresh
Vaswani |
Appointment as nonexecutive Independent Director |
July 4, 2024 |
Mr. Dileep |
Completion of tenure |
December 26, |
Choksi |
as non-executive Independent Director |
2024 |
Ms. Anuradha |
Appointment as non- |
March 12, |
Bhatia |
executive Independent Director |
2025 |
Particulars of Senior Management Personnel (SMP) as per Companies Act, 2013 and SEBI
(Listing Obligations and Disclosure Requirements) Regulations, 2015 and changes during the
year ended March 31, 2025
Changes in the SMP during the year ended March 31, 2025
Name of SMP |
Appointment/ Resignation/ Cessation of tenure/Retirement/
Superannuation/ Re-designation/ Withdrawal of nomination |
With effect from |
Mr. Ganessan Soundiram |
Designated as Chief Technology Officer |
May 1, 2024 |
Mr. Rajiv Adhikari |
Designated as Head - Corporate Communications |
May 1, 2024 |
Ms. Sonali Chandak |
Resigned as a Company Secretary |
May 21, 2024 |
Ms. Priya Nair |
Appointed as a Company Secretary |
May 21, 2024 |
Mr. Deepak Kinger |
Re-designated as Chief Risk and Governance Officer |
July 24, 2024 |
Mr. Anand Desai |
Appointment as Chief Compliance Officer |
July 24, 2024 |
List of SMP as on the date of this Report: Sr
No Name of SMP Designation
1 |
Mr. Judhajit Das |
2 |
Mr. Amit Palta |
3 |
Mr. Manish Kumar |
4 |
Mr. Deepak Kinger |
5 |
Mr. Souvik Jash |
6 |
Mr. Dhiren Salian |
7 |
Ms. Priya Nair |
8 |
Mr. Ganessan Soundiram |
9 |
Mr. Rajiv Adhikari |
10 |
Mr. Anand Desai |
Chief - Human Resources and Operations
Chief Product and Distribution Officer
Chief Investment Officer
Chief Risk and Governance Officer
Appointed Actuary Chief Financial Officer Company Secretary Chief Technology Officer
Head - Corporate Communications
Chief Compliance Officer
Separate meeting of independent Directors
During FY2025, a separate meeting of the Independent Directors was held on April 23,
2024.
Retirement by rotation
In accordance with Section 149, Section 152 of the CA2013 and the Articles of
Association of the Company, Mr. Anuj Bhargava (DIN: 02647635) would retire by rotation at
the ensuing AGM. Mr. Anuj Bhargava, being eligible has offered himself for re-appointment.
Criteria for appointment of a Director and those in senior management positions that is
who may be appointed as key managerial person/personnel (KMP) or as senior managerial
personnel (SMP)
The Company with the approval of its Board Nomination & Remuneration Committee
(Committee) has put in place a criteria for appointment of Directors and those in senior
management positions that is who may be appointed as key managerial person/ personnel
(KMP) or as senior managerial personnel (SMP) (Criteria). The policy has been framed based
on the broad principles as outlined hereinafter. The Committee evaluates the composition
of the Board and vacancies arising in the Board from time to time. The Committee while
recommending candidature of a Director considers the special knowledge and areas of
expertise possessed by the candidate. The Committee assesses the fit and proper
credentials of the candidate and the companies/ entities with which the candidate is
associated either as a director or otherwise and as to whether such association is
permissible under IRDAI (Corporate Governance for insurers) Regulations, 2024 (IRDAI CG
Regulations) and Master Circular on Corporate Governance for Insurer, 2024 (Master
Circular) and the internal norms adopted by the
Company. For the above assessment, the Committee is guided by the Rules, regulations,
circulars issued by CA2013, IRDAI, SEBI, in this regard.
The Committee also evaluates the prospective candidate for the position of a Director
from the perspective of the criteria for independence. For a Non-Executive Director to be
classified as Independent he/she must satisfy the criteria of independence as prescribed
and sign a declaration of independence. The Board will review the same and determine the
independence of a Director after being taking note of the recommendations of the
Committee.
The KMP and SMP shall be personnel as defined under the CA2013, SEBI Listing
Regulations and IRDAI Master Circular and any amendments thereto. The Committee shall
recommend the candidature for KMP or SMP who shall have proven skills, performance track
record, relevant competencies, maturity and experience in handling core functions relevant
to an organisation.
The criteria has also been hosted on the website of the Company and can be accessed on
the link: https:// www.iciciprulife.com/about-us/corporate-policies.html.
Remuneration Remuneration policy
The Company has in place a policy on Compensation & Benefits (Compensation
Policy) for Managing Director & CEO, other wholetime Directors, non-executive
Directors, Key Management Person (KMP), Senior Management Personnel (SMP) and other
employees.
Further details with respect to the Compensation policy are provided under the section
titled Compensation & Benefit policy, which has also been hosted on the
website of the Company and can be accessed on the link: https://www.iciciprulife.
com/about-us/corporate-policies.html.
Details of remuneration paid to wholetime Directors
The Board Nomination and Remuneration Committee (BNRC) determines and recommends to the
Board the remuneration, including performance bonus and non-cash benefits and perquisites,
payable to the wholetime Directors.
The following table sets out the details of remuneration (including perquisites and
retiral
benefits) paid to the wholetime Director during FY2025:
Particulars |
Details of |
remuneration (^) |
|
Mr. Anup Bagchi |
Basic |
30,554,160 |
Variable pay1 |
9,054,188 |
Allowances2 and perquisites3 |
30,044,994 |
Contribution to provident fund |
3,666,504 |
Contribution to gratuity fund4 |
2,545,152 |
Stock options of the Company (Numbers) |
|
Granted in FY2025 |
400,500 |
Granted in FY2024 |
- |
Note: For the year ended March 31, 2025 the remuneration details pertain to the amount
paid/options granted during the period of service as per IRDAI approval
^Variable pay is the actual amount paid during FY2025 pertaining to performance of
previous Financial year. It does not include the variable pay for performance of FY2025 or
previous Financial years, that is payable in FY2026 or thereafter
2
Allowances also include Superannuation and
contribution to NPS.
3
Perquisites are evaluated as per Income-Tax rules wherever applicable, and
exclude perquisites on Provident Fund and perquisites on exercise of stock options, if
any. Stock options exercised during the year does not constitute remuneration paid to the
wholetime directors and accordingly is not considered here.
4
Provision towards gratuity is actuarially valued for the group of all eligible
employees on an overall basis, however, for the purpose of this section, annual
contribution towards gratuity fund of the Company as approved by BNRC/Board has been
given.
Details of remuneration paid to non-executive Directors
As provided in the Articles of Association of the Company, the fees payable to the
non-executive independent Directors for attending a Meeting of the Board or Committee
thereof is decided by the Board of Directors from time to time within the limits
prescribed by the CA2013.
For FY2025, the Company has paid ' 100,000 as sitting fees for each meeting of the
Board, ' 100,000 for each Board Audit Committee meeting and ' 50,000 as sitting fees for
each Meeting of other Board Committee meetings attended. This amount is within the limits
prescribed as per Rule 4 of Companies (Appointment and Remuneration of Managerial
Personnel) Rules, 2014 of the CA2013.
The members of the Company at the Annual General Meeting (AGM) held on June 28, 2024,
have approved the payment of compensation in form of profit related commission up to ' 2
million per annum, each year, effective from financial year commencing from April 1, 2024,
to each non-executive Independent Director of the Company. The payments are subject to the
regulatory provisions applicable to the
Company, if any and availability of net profits at the end of each financial year.
Further, the members of the Company at the AGM held on July 28, 2023 have approved the
remuneration in the form of profit related commission to Chairperson designated in the
category of non-executive, Independent Director of the Company at ' 2 million per annum
effective from financial year commencing from April 1, 2024. Sitting fees paid to
independent Directors are outside the purview of the above limits.
Further, Mr. M. S. Ramachandran, non-executive Independent Director, Chairman of the
Company, was also provided an office, including its maintenance, at the Company's expense,
for attending to his duties as the Chairman of the Company, till June 29, 2024, pursuant
to the resolution passed by the members of the Company on October 30, 2020, through postal
ballot.
The details of the sitting fees and commission are as below:
Sitting fees paid to independent Directors for the financial year ended March 31, 2025:
Name of the Director |
Amount (^ in million) |
Mr. M. S. Ramachandran |
0.40 |
Mr. Dilip Karnik |
2.15 |
Mr. R. K. Nair |
2.50 |
Mr. Dileep Choksi |
1.55 |
Ms. Vibha Paul Rishi |
2.25 |
Mr. Naved Masood |
1.20 |
Mr. Suresh Vaswani |
1.60 |
Ms. Anuradha Bhatia |
0.10 |
Commission to be paid to independent Directors for the financial year
ended March 31, 2025:
Name of the Director |
Amount (^ in million) |
Mr. M. S. Ramachandran |
0.49 |
Mr. Dilip Karnik |
2.00 |
Mr. R. K. Nair |
2.00 |
Mr. Dileep Choksi |
1.47 |
Ms. Vibha Paul Rishi |
2.00 |
Mr. Naved Masood |
2.00 |
Mr. Suresh Vaswani |
1.48 |
Ms. Anuradha Bhatia |
0.11 |
Remuneration disclosures pursuant to IRDAI Master Circular on Corporate Governance for
Insurers, 2024
Pursuant to IRDAI Master Circular on Corporate Governance for Insurers, 2024 issued
vide reference no. IRDAI/F&I/CIR/MISC/82/5/2024 dated May 22, 2024, the Company is
required to make the following disclosures on remuneration in the Annual Report:
Compensation policy and practices
1. Qualitative disclosures
A) I nformation relating to the composition and mandate of the Nomination and
Remuneration Committee
Name, composition and mandate of the main body overseeing remuneration:
The Board Nomination and Remuneration Committee (BNRC/Committee) is the body which
oversees aspects pertaining to remuneration. The functions of the Committee include
identifying persons who are qualified to become Directors and who may be appointed in
senior management in accordance with the criteria laid down and recommending to the Board
their appointment & removal and formulating a criteria and specifying the manner for
effective evaluation of every individual director's performance, evaluation of the
performance of the Board and its Committees, and reviewing its implementation and
compliance; considering to extend or continue the term of appointment of the Independent
Directors, on the basis of the report of performance evaluation of Independent Directors;
determining and recommending to the Board a policy relating to the remuneration for the
Directors, the CEO, key management persons and other employees in alignment with
applicable guidelines and framework; recommending to the Board all remuneration, in
whatever form, payable to senior management; ensuring that the level and composition of
remuneration is reasonable and sufficient to attract, retain and motivate Directors of the
quality required to run the Company successfully; ensuring that the relationship of
remuneration to performance is clear and meets appropriate performance benchmarks;
approving the compensation program and ensuring that remuneration to Directors, key
management persons and senior management involves a balance between fixed and incentive
pay reflecting short and long-term performance objectives appropriate to the working of
the Company and its goals; formulating the criteria for determining qualifications,
positive attributes and independence of a Director; devising a policy on diversity of the
Board; considering and approving employee stock option schemes and administering &
supervising the same; ensuring that the proposed appointments/ re-appointments of key
management persons or Directors are in conformity with the Board approved policy on
retirement/ superannuation; scrutinising the declarations of intending applicants before
the appointment/ re-appointment/election of Directors by the shareholders at the annual
general meeting;
and scrutinising the applications and details submitted by the aspirants for
appointment as the key management person and to make independent/ discreet references,
where necessary, well in time to verify the accuracy of the information furnished by the
applicant.
External consultants whose advice has been sought, the body by which they were
commissioned and in what areas of the remuneration process:
The Company employed the services of reputed consulting firms for market benchmarking
in the area of compensation.
Scope of the Company's remuneration policy (e.g. by regions, business lines), including
the extent to which it is applicable to foreign subsidiaries and branches:
The Company's Policy on Compensation & Benefits (Compensation Policy)
for Managing Director & CEO, other Wholetime Directors, non-executive Directors, Key
Management Person (KMP), Senior Management Personnel (SMP) and other employees was last
amended and approved by the BNRC at its Meeting held on April 23, 2024 and July 22, 2024
respectively and the Board at its Meeting held on April 23, 2024, and July 23, 2024
respectively.
Type of employees covered and number of such employees:
All employees of the Company are governed by the Compensation Policy. The total number
of permanent employees governed by the Compensation Policy of the Company at March 31,
2025 was 20,035.
B) Information relating to the design and structure of remuneration process and the key
features and objectives of remuneration policy.
Key features and objectives of remuneration policy:
The Company has historically followed prudent compensation practices under the guidance
of the Board and the BNRC. The Company's approach to compensation is based on the ethos of
meritocracy and fairness within the framework of prudent risk management. This approach
has been incorporated in the Compensation Policy, the key elements of which are given
below:
Effective governance of compensation:
The Company follows prudent compensation practices under the guidance of the BNRC and
the Board. The BNRC has the oversight for framing, review and implementation of the
Company's Compensation Policy on behalf of the Board, and shall work in close coordination
with the Board Risk Management Committee for an integrated approach to the formulation of
the Compensation Policy where required.
The decision relating to the remuneration of the Managing Director and CEO (MD &
CEO), other wholetime Directors and KMPs/SMPs is reviewed and approved by the BNRC and the
Board. The BNRC and the Board approves the Key Performance Indicators (KPIs) and the
performance threshold for payment of performance bonus, if applicable. The BNRC assesses
business performance against the KPIs as prescribed by IRDAI. Based on its assessment, it
makes recommendations to the Board regarding compensation for MD & CEO and other
wholetime Directors, performance bonus and long-term pay for all eligible employees,
including senior management and key management persons.
Alignment of compensation philosophy with prudent risk taking:
The Company seeks to achieve a prudent mix of fixed and performance-linked variable
pay, with a higher proportion of variable pay at senior levels. For the MD & CEO and
other wholetime Directors and KMPs/SMPs, compensation is sought to be aligned to the
pre-defined performance objectives of the Company. In addition, the Company has an
Employees Stock Option Scheme and an Employee Stock Unit Scheme aimed at enabling
employees to participate in the long-term growth and financial success of the Company
through stock option grants/stock unit grants that vest over a period of time.
Whether the Remuneration Committee reviewed the firm's remuneration policy during the
past year, and if so, an overview of any changes that were made:
The BNRC reviewed the Company's Compensation Policy at its meetings held on April 23,
2024 and July 22, 2024 respectively.
Insurance Regulatory and Development Authority of India (IRDAI) had released
Master Circular on Corporate Governance for Insurers, 2024' on May 22, 2024
Subsequently, the Compensation Policy was amended, and accordingly the
amendments were proposed to the Committee, in line with the Master Circular on Corporate
Governance for Insurers, 2024. The key changes involved including a clause on deferment of
cash component of performance bonus/PLR for all other employees, a clause on maximum cap
on performance-linked variable pay and long-term pay together of 300% for all employees,
and a clause on hedging to disallow hedging of compensation including ESOPs/ESUs for WTDs
& KMP/SMP and all
other employees. Additionally, Embedded Value and Value of New Business were added as
parameters to the minimum parameters to be followed to determine performance assessment of
WTDs, KMPs and SMPs. Consequent to the introduction of deferral of variable pay for all
other employees, the section on Claw-back was extended to also include Malus.
The revised compensation policy was approved by the BNRC at its meetings held on April
23, 2024 and July 22, 2024 and the Board at its meetings held on April 23, 2024 and July
23, 2024 respectively.
Description of the ways in which current and future risks are taken into account in the
remuneration processes.
The Company follows prudent compensation practices under the guidance of the
Board and the Board Nomination & Remuneration Committee (BNRC). The Company's approach
to compensation is based on the ethos of meritocracy and fairness within the framework of
prudent risk management. The performance rating assigned to employees is based on an
assessment of performance delivered against a set of defined performance objectives. These
objectives are balanced in nature and comprise a holistic mix of financial, customer,
people, process, quality, compliance objectives and/or any other parameters as may be
deemed fit.
For the MD & CEO, other wholetime Directors and KMPs/SMPs, compensation is
sought to be aligned to pre-defined performance objectives of the Company which are
approved by the BNRC and the Board.
For the MD & CEO, other wholetime Directors and KMPs/SMPs, the quantum of
variable pay does not exceed 300% (as stipulated in the Compensation Policy) of total
fixed pay in a year; a minimum of 50% of the variable pay (as stipulated in the
Compensation Policy) will be under deferment. If the bonus amount is under ' 25 lacs, the
deferment shall not be applicable. The deferral period would be spread over a minimum
period of three years (deferment period). The frequency of vesting will be on annual basis
and the first vesting shall not be before one year from the commencement of deferral
period. The vesting shall be no faster than a pro rata basis. Additionally, vesting will
not be more frequent than on a yearly basis.
Ensuring balance in setting performance objectives, capping the payout of
performance bonus and following an annual payout cycle for variable pay ensures that
prudent behaviour is suitably encouraged and rewarded.
The deferred part of the variable pay (performance bonus and long term pay in
the form of stock options/stock units) for wholetime Directors and KMPs/ SMPs is subject
to malus, under which, the Company will prevent vesting of all or part of the variable pay
in the event of act of willful or gross misconduct or neglect, the commission of felony,
fraud, misappropriation, embezzlement, breach of trust or an offence involving moral
turpitude or breach of integrity, gross or willful insubordination, or materially
inaccurate financial statements due to the result of misconduct including fraud, or poor
compliance in respect of corporate governance and regulatory matters, or any other act
detrimental to the interest of the Company. The details of malus and clawback arrangements
are defined in the Company's Compensation Policy. In addition, under the events mentioned
above and defined in the Compensation Policy, as per clawback arrangements with wholetime
Directors and KMPs/SMPs, the employee agrees to return, in case asked for, the previously
paid variable pay to the Company.
Due process including inquiries or investigations as required and/or adherence
to principles of natural justice are ensured prior to conclusion on the above events of
breaches and which would form the basis of decisions. Error of judgment shall not be
construed to be breaches.
Description of the ways in which the Company seeks to link performance during a
performance measurement period with levels of remuneration.
The Company's approach to compensation is based on the ethos of meritocracy and
fairness within the framework of prudent risk management. The extent of variable pay for
individual employees is linked to individual performance for sales frontline employees and
to individual & organisation performance for non-sales frontline employees &
employees in the management cadre. For the latter, the performance rating assigned is
based on assessment of performance delivered against a set of defined performance
objectives. These objectives are balanced in nature, and comprise a holistic mix of
financial, customer, people, process, quality and compliance
objectives and/or any other parameters as may be deemed fit. For the MD & CEO,
other wholetime Directors and KMPs/SMPs to ensure effective alignment of compensation with
prudent risk parameters, the Company takes into account certain minimum parameters (as
defined in the Compensation Policy and in line with the IRDAI Master Circular) to
determine the performance assessment along with any other pre-defined performance
objectives of the Company as may be determined by the BNRC and the Board.
2. Quantitative Disclosures
The following table sets forth, for the period indicated, the details of quantitative
disclosure for remuneration of the Managing Director & CEO:
Particulars |
At March 31, 2025 |
Number of WTD/ CEO/ MD having received a variable remuneration award
during the financial year |
1 |
Number and total amount of sign on awards made during the financial
year |
Nil |
Details of guaranteed bonus, if any, paid as joining/ sign on bonus |
Nil |
Total amount of outstanding deferred remuneration split into cash,
shares, share linked instruments and other forms |
Given Below |
Total amount of deferred remuneration paid out in the financial year |
Given Below |
Breakup of amount of remuneration awarded for the financial year to
show fixed and variable, deferred and non deferred |
Given Below |
Remuneration and other payments made during the Financial Year to MD/CEO/WTD
SI. No. Name of the MD/ CEO/ WTD |
Designation |
Fixed pay |
Variable pay |
Total of fixed and variable pay (c ) +(f )
Deferred |
Amount
debited
to
revenue
a/c |
Amount debited to profit and loss a/c |
Value of joining/ sign on bonus |
Retirement benefits like gratuity/ pension etc. paid
during the year |
Amount
of
deferred remuneration of earlier years
paid/settled during the year |
Pay and allowances (a) |
Perquisites etc. (b) |
Total (c )= (a) + (b) |
Cash components (d) |
Non-cash components (e) |
Total (f )= (d) + (e) |
Paid Deferred |
Settled |
Deferred |
Paid/ Settled Deferred |
Anup |
MD and |
|
|
|
|
|
|
|
|
|
|
|
|
|
1 Bagchi |
CEO |
662 |
6 |
668 |
- 74 |
|
|
- 74 |
742 |
400 |
342 |
|
|
91 |
Total |
|
662 |
6 |
668 |
- 74 |
- |
- |
- 74 |
742 |
400 |
342 |
- |
- |
91 |
Notes:
1
During the year, Anup Bagchi was granted 400,500 equity options as deferred
non-cash variable pay for the performance in FY2024 at the closing price on the recognised
stock exchange having higher trading volume, on the date immediately prior to the date of
meeting of the BNRC scheduled to consider granting the said options under the Company's
Employee Stock Option Scheme. The Company follows intrinsic value method and no charge was
recognised in the Revenue account and the Profit and Loss account, accordingly Nil amount
has been reported as remuneration against these grants.
2Deferred variable pay
amounting to ' 91 lakhs of Anup Bagchi pertaining to previous year paid in current year
has been considered for the purpose of calculating remuneration paid in excess of
specified limit of ' 400 lakhs.
Details of Outstanding Deferred Remuneration of MD/CEO/WTD as at March 31, 2025
Sr. No |
Name of WTD/ MD/ CEO |
Designation |
Remuneration pertains to FY |
Nature of remuneration outstanding |
Amount outstanding (in Lakhs) |
1 |
Anup Bagchi1 |
MD/CEO |
FY2024 |
Performance Bonus |
91 |
Total |
|
|
|
|
91 |
|
|
|
FY2022 |
|
49 |
2 |
N. S. Kannan2 |
MD/CEO |
FY2023 |
Performance Bonus |
109 |
|
|
|
FY2024 |
|
20 |
Total |
|
|
|
|
269 |
Notes:
1
Anup Bagchi was appointed as Executive Director and Chief Operating Officer
w.e.f. May 1, 2023 and as Managing Director & CEO w.e.f. June 19, 2023
2
N. S. Kannan ceased to be Managing Director & CEO w.e.f. June 19, 2023
Disclosures required with respect to Section 197(12) of the CA2013
The ratio of the remuneration of each Director to the median employee's remuneration
and such other details in terms of Section 197(12) of the CA2013 read with Rule 5 of the
Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014. For the
purpose of this section, aspects of fixed remuneration which includes basic salary,
supplementary allowance and retirals (provident fund, gratuity and superannuation) have
been considered and have been annualised.
(i) The ratio of the remuneration of each director to the median remuneration of the
employees, who are part of annual bonus plan (excluding frontline sales), of the Company
for the financial year:
Mr. Anup Bagchi, Managing Director & CEO 68:1
(ii) The percentage increase in remuneration of each wholetime Director, Chief
Financial Officer, Chief Executive Officer, Company Secretary or Manager, if any, in the
financial year:
The percentage increase in remuneration of wholetime Director i.e. Managing Director
& CEO, Chief Financial Officer, and Company Secretary ranged between 2% and 7%.
(iii) The percentage increase in the median remuneration of employees, who are part of
annual bonus plan (excluding frontline sales), in the financial year:
The percentage increase in the median remuneration of employees, who are part of annual
bonus plan, in the financial year was around 16.8 %
(iv) The number of permanent employees on the rolls of Company:
The number of employees as on March 31, 2025 is 20,035.
(v) Average percentile increase already made in the salaries of employees other than
the managerial personnel in the last financial year and its comparison with the percentile
increase in the managerial remuneration and justification thereof and point out if there
are any exceptional circumstances for increase in the managerial remuneration:
The average percentage increase in the salaries of total employees other than the key
management persons for fiscal 2025 was around 13.0%, while the average increase in the
remuneration of the key management person was in the range of 2% to 7%.
(vi) Affirmation that the remuneration is as per the remuneration policy of the
Company:
Employee Stock Option Scheme (ESOS)
The Company granted options to its employees under its Employees Stock Option Scheme,
prior to listing, further
to the approval of its Employees Stock Option Scheme - 2005. This pre-IPO Scheme shall
be referred to as ESOS 2005' or Scheme'. The Scheme had six tranches namely
Founder, 2004-05, 2005-06, 2006-07, Founder II and 2007-08, pursuant to which shares have
been allotted and listed in accordance with the in-principle approval extended by the
stock exchanges. All six tranches under the pre-IPO Scheme stand lapsed as on March 31,
2025. The Scheme was instituted vide approval of its members at the Extra-Ordinary General
Meeting (EGM) dated March 28, 2005 and subsequently amended by the members of the Company
vide its EGM dated February 24, 2015.
The Scheme was ratified and amended by the members of the Company at its Annual General
Meeting held on July 17, 2017 which is in compliance with the SEBI (Share Based Employee
Benefits) Regulations, 2014 (referred to as the Revised Scheme').
The meeting of Board Nomination and Remuneration Committee (BNRC) and the Board held on
April 24, 2019 had approved the amendment to the definition of Exercise
Period. The revision to the definition was approved by the members of the Company at
its Annual General Meeting held on July 17, 2019.
Further, the meeting of Board Nomination and Remuneration Committee (BNRC) and the
Board held on April 17, 2021 and April 19, 2021 respectively had approved the increase in
the limit of the number of shares issued or issuable since March 31, 2016 pursuant to the
exercise of any Options granted to the Eligible Employees issued pursuant to the Scheme or
any other stock option scheme of the Company, by 0.90% of the number of shares issued as
on March 31, 2016, i.e. from a limit of 2.64% of the number of shares issued as on March
31, 2016 to 3.54%. The revision to the limit was approved by the members of the Company at
its Annual General Meeting held on June 25, 2021.
As per the Revised Scheme, the aggregate number of shares issued or issuable since
March 31, 2016 pursuant to the exercise of any Options granted to the Eligible Employees
issued pursuant to the Scheme or any other stock option scheme of the Company, shall not
exceed 3.54% of the number of shares issued at March 31, 2016. Further, pursuant to the
Revised Scheme the maximum number of Options that can be granted to any Eligible Employee
in a financial year shall not exceed 0.1% of the issued Shares of the Company at the time
of grant of Options. The Revised Scheme provides for a minimum period of one year between
the grant of Options and vesting of Options. The exercise price shall be determined by the
Board Nomination & Remuneration Committee in concurrence with the Board of Directors
of the Company on the date the options are granted and shall be reflected in the award
confirmation. Shares are allotted/issued to all those who have exercised their Options, as
granted by the Board/BNRC of the Company in accordance with the criteria ascertained
pursuant to the Company's Compensation and Benefit policy.
Pursuant to the SEBI (Share Based Employee Benefits) Regulations, 2014, the disclosures
are available on the website of the Company at the following link https://www.iciciprulife.com/about-us/corporate-policies.html?ID=about-corp.
The salient features of tranches issued under the Revised Scheme are as stated below:
Scheme |
Date of Grant |
Number of options granted |
Maximum term for exercising the options granted |
|
Graded Vesting Period |
|
Mode of settlement |
1st Year |
2nd Year |
3rd Year |
4th Year |
2017-18 |
July 25, 2017 |
6,56,300 |
Exercise period would commence from the date of vesting and expire on
completion of ten years from the date of vesting of stock options |
30% of options granted |
30% of options granted |
40% of options granted |
- |
|
2018-19 |
April 24, 2018 |
21,67,900 |
|
|
|
|
|
|
2018-19 Special Options |
April 24, 2018 |
49,80,250 |
|
- |
- |
50% of options granted |
50% of options granted |
|
2018-19 Joining Options |
January 22, 2019 |
1,56,000 |
|
|
|
|
|
|
2019-20 |
April 24, 2019 |
49,93,600 |
|
|
|
|
|
|
2019-20 Joining Options |
July 24, 2019 |
80,000 |
|
|
|
|
|
|
2020-21 |
May 10, 2020 |
50,72,200 |
|
|
|
|
|
|
2020-21 Joining Options |
June 11, 2020 |
25,000 |
|
|
|
|
|
|
2020-21 Joining Options |
January 27, 2021 |
50,000 |
Five years from the date of vesting of stock options |
|
|
|
|
Equity |
2021-22 |
April 19, 2021 |
50,01,600 |
|
|
|
|
|
2021-22 Joining Options |
July 20, 2021 |
5,500 |
|
30% of options granted |
30% of options granted |
40% of options granted |
|
|
2021-22 Joining Options |
October 19, 2021 |
5,000 |
|
- |
|
2021-22 Joining Options |
January 18, 2022 |
49,500 |
|
|
|
|
|
|
2022-23 |
April 16, 2022 |
53,36,930 |
|
|
|
|
|
|
2022-23 Joining Options |
April 16, 2022 |
99,300 |
|
|
|
|
|
|
2023-24 |
April 20, 2023 |
69,50,700 |
|
|
|
|
|
|
2023-24 Joining Options |
January 17, 2024 |
56,100 |
Five years from the date of vesting of stock options |
|
|
|
|
|
2024-25 |
April 23, 2024 |
2,39,600 |
Five years from the date of vesting of stock options |
|
|
|
|
|
Note: The exercise price for all the options granted by the Board/BNRC of the Company,
after listing (as tabulated above), is based on the last closing price of the shares of
the Company at a domestic stock exchange having highest volumes on the immediate business
day prior to grant.
Exercise price of all the options outstanding for all years/quarter for tranches
2017-18, 2018-19, 2018-19 Special Options and 201819 Joining Options, 2019-20, 2019-20
Joining Options, 2020-21, 2020-21 Joining Options (1), 2020-21 Joining Options (2),
2021-22, 2021-22 Joining Options (1), 2021-22 Joining Options (2), 2021-22 Joining Options
(3), 2022-23, 2022-23 Joining Options, 2023-24, 2023-24 Joining Options, 2024-25 schemes
is ' 468.60, ' 388.40, ' 388.40, ' 351.65, ' 369.50, ' 383.10, ' 400.10, ' 396.95, '
501.90, ' 451.05, ' 626.25, ' 656.80, ' 615.65, ' 541.00, ' 541.00, ' 445.60, ' 522.20,
and ' 580.30 respectively.
Particulars of options for the year ended March 31, 2025 are given below:
Options granted |
640,100 |
Options forfeited/ lapsed |
183,430 |
Options vested |
5,331,719 |
Options exercised# |
4,651,085 |
Total number of options in force* |
24,255,595 |
Number of shares allotted pursuant to exercise of options1 |
4,705,535 |
Extinguishment or modification of options |
Nil |
Amount realised by exercise of options (?) |
1,884,362,799 |
Note: For details on changes in the number of options due to actions like grants,
forfeitures, vesting exercise, lapsation during the year and resultant options outstanding
at the end of the year vis-a-vis start of the year, refer Notes to accounts.
Options exercised' includes options exercised by employees where payments
have been received and does not include options exercised by employees where payments are
due * Total number of options in force' includes options exercised by employees
where payment is yet to be received 1 54,450 options exercised in March 2024
(FY2024) were allotted in April 2024 (FY2025).
The following key management persons and senior management personnel (SMP), other than
wholetime Director, were granted stock options of the Company
up to a maximum of 66,100 options to an individua aggregating to 239,600 options during
FY2025
Sr.
No. |
Name |
Designation |
1 |
Mr. Judhajit Das |
Chief - Human Resources & Operations |
2 |
Mr. Amit Palta |
Chief Product & Distribution Officer |
3 |
Mr. Deepak Kinger |
Chief Risk and Governance Officer |
4 |
Mr. Manish Kumar |
Chief Investment Officer |
No employee was granted options during any one year equal to or exceeding 0.1% of the
issued equity shares of the Company at the time of the grant.
Out of the total outstanding options at April 1, 2024, 5,331,719 options vested during
the year ended March 31, 2025 and ' 18,844 Lakhs was realised by exercise of options
during the year ended March 31, 2025. Amount realized by exercise of options does not
include options exercised by employees during the financial year where payments are
received after March 31, 2025.
The Company follows intrinsic value method. During the year ended March 31, 2025, the
Company has recognised a compensation cost of ' Nil (year ended March 31, 2024: ' Nil) as
the intrinsic value of the unit.
The weighted average remaining contractual life of options outstanding at the end of
the year is as follows:
|
At March 31, 2025 |
At March 31, 2024 |
Exercise price range (in ') |
Options outstanding |
Weighted average remaining contractual life (in years) |
Options outstanding |
Weighted average remaining contractual life (in years) |
468.60 |
506,300 |
4.4 |
565,400 |
5.4 |
388.401 |
2,320,815 |
1.3 |
3,936,710 |
2.4 |
369.50 |
2,034,470 |
1.2 |
3,389,200 |
2.3 |
383.10 |
- |
- |
37,500 |
3.2 |
400.10 |
3,691,090 |
3.2 |
4,201,610 |
4.2 |
396.95 |
- |
- |
- |
- |
451.05 |
3,933,500 |
3.1 |
4,421,860 |
4.2 |
626.25 |
- |
- |
- |
- |
656.80 |
4,000 |
3.6 |
5,000 |
4.6 |
615.65 |
49,500 |
3.9 |
49,500 |
4.9 |
541.00* |
4,667,600 |
4.1 |
5,071,030 |
4 |
445.60 |
6,352,120 |
5.2 |
6,716,100 |
6.2 |
522.20 |
56,100 |
5.9 |
56,100 |
6.5 |
580.30 |
640,100 |
6.2 |
- |
- |
Total |
24,255,595 |
3.6 |
28,450,010 |
4.2 |
includes FY2018-19 options and FY2018-19 special options 'includes FY2022-23 options
and FY2022-23 joining options
For the year ended March 31 2025, ICICI Bank Limited (the Holding Company)
has not granted options to the employees of ICICI Prudential Life insurance Co. Ltd.
(Previous year grant: Nil) and accordingly no cost was recognised.
Employee Stock Unit Scheme (Unit Scheme)
In addition, the ICICI Prudential Employees Stock Unit Scheme - 2023' (Unit
Scheme), designed in accordance with SEBI Regulations and other applicable regulations,
was approved by the Committee at its meeting held on June 10, 2023. Subsequent to the
approval of the Unit Scheme by the Board at its meeting held on June 10, 2023 it was
approved by the shareholders of the Company at its meeting held on July 28, 2023.
The maximum number of Shares that can be issued under this Unit Scheme shall be
1,45,00,000 (One Crore Forty Five Lacs). Each Unit on Exercise will entitle the
Participant to 1 (One) Share. The Grants under the Unit Scheme shall be made in one or
more tranches as may be determined by the Committee over a period of 6 (six) years from
the date of approval of the Unit Scheme by the shareholders. The maximum number of Units
granted to any Eligible Employee shall not exceed 60,000 (sixty thousand) Units in any
financial year.
The vesting shall commence on the expiry of minimum period of one (1) year from the
date of Grant of the Units and the Vesting Period would be spread over a minimum period of
three (3) years from the date of Grant of the Units. The Committee has the authority to
prescribe the Exercise Period not exceeding 5 years from date of vesting within which the
Participant can Exercise the vested Units and that would lapse on failure to Exercise the
same within the Exercise Period. The Exercise Price shall be the face value of the Shares
of the Company.
The salient features of the tranche issued under the Employee Stock Unit Scheme is as
stated below:
Scheme |
Date of Grant |
Number of options granted |
Maximum term for exercising the options granted |
Graded Vesting Period |
Mode of |
1st Year |
2nd Year |
3rd Year |
4th Year |
settlement |
2024-25 |
April 23, 2024 |
1,710,600 |
Five years from the date of vesting of stock options |
30% of options granted |
30% of options granted |
40% of options granted |
|
Equity |
Note: The exercise price for all the units granted by the Board/BNRC of the Company,
after listing (as tabulated above), is the face value of the Shares of the Company.
Besides continuity of employment, Vesting shall also be dependent on achievement of any
corporate performance parameter(s) as the Committee may determine, including but not
limited to:
Embedded Value Operating Profit; and/or
Value of New Business; and/or
Any other parameter(s), if any, as the Committee may determine
Particulars of units for the year ended March 31, 2025 are given below:
Units granted |
1,710,600 |
Units forfeited/ lapsed |
9,830 |
Units vested |
3,160 |
Units exercised |
- |
Total number of units in force |
1,700,770 |
Number of shares allotted pursuant to exercise of units1 |
- |
Extinguishment or modification of units |
Nil |
Amount realized by exercise of units (' |
Nil |
Note: For details on changes in the number of units due to actions like grants,
forfeitures, vesting exercise, lapsation during the year and resultant units outstanding
at the end of the year vis-a-vis start of the year, refer Notes to accounts.
The following key management persons and senior management personnel (SMP), other than
wholetime Director, were granted stock units of the Company up to a maximum of 30,680
units to an individual, aggregating to 189,890 units during FY2025.
Sr.
No. |
Name |
Designation |
1 |
Mr. Judhajit Das |
Chief - Human Resources & Operations |
2 |
Mr. Amit Palta |
Chief Product & Distribution Officer |
3 |
Mr. Deepak Kinger |
Chief Risk and Governance Officer |
4 |
Mr. Manish Kumar |
Chief Investment Officer |
5 |
Mr. Souvik Jash |
Appointed Actuary |
6 |
Mr. Dhiren Salian |
Chief Financial Officer |
7 |
Mr. Ganessan Soundiram# |
Chief Technology Officer |
8 |
Mr. Anand Desai" |
Chief Compliance Officer |
9 |
Mr. Rajiv Adhikari# |
Head - Corporate Communications |
10 |
Ms. Priya Nair' |
Company Secretary |
Designated KMP as per IRDAI Regulations effective May 1, 2024 "Designated
KMP as per IRDAI Regulations effective July 24, 2024 'Designated KMP as per CA2013,
Listing Regulations and IRDAI Regulations effective May 21, 2024
Out of the total outstanding units on April 23, 2024, 3160 units vested during the year
ended March 31, 2025, and ' Nil was realized by exercise of units during the year ended
March 31, 2025.
The Company follows intrinsic value method. During the year ended March 31, 2025 the
Company has recognized a compensation cost of ' 5,008 lakhs( March 31, 2024: ' Nil) as the
intrinsic value of the unit exercised.
The weighted average remaining contractual life of options outstanding at the end of
the year is as follows:
|
At March 31, 2025 |
At March 31, 2024 |
Exercise price range (in ') |
Options outstanding |
Weighted average remaining contractual life (in years) |
Options outstanding |
Weighted average remaining contractual life (in years) |
10 |
^?1,700,770 |
6.2 |
_ |
- |
Fair value methodology
The assumptions considered in the pricing model for the ESOPs and ESUs granted during
the year are as below:
Particulars |
Mar 31, 2025 |
Mar 31, 2024 |
Basis |
Risk-free |
7.08% to |
6.94% to |
G-Sec yield at |
interest
rate |
7.12% |
7.05% |
grant date for tenure equal to the expected term of ESOPs |
Expected |
3.50 to |
3.50 to |
Simplified method |
life of the |
5.58 |
5.50 |
(average of |
options/
units |
years |
years |
minimum and maximum life of options) |
Dividend |
0.10% |
0.11% to |
Based on recent |
yield |
|
0.12% |
dividend declared |
Expected |
14.48% |
14.81% |
Based on |
volatility |
to 8.85% |
to 21.55% |
historical volatility determined on the basis of Nifty 50 |
Had the Company followed fair value method based on Black Scholes model valuing its
options and units compensation cost for the year ended would have been higher by ' 4,467
lakhs (March 31, 2024: ' 8,455 lakhs) in case of ESOS and ' 7 lakhs in case of ESU and the
proforma profit after tax would have been ' 114,433 lakhs (March 31, 2024: ' 76,784
lakhs). On a proforma basis, the Company's basic and diluted earnings per share would have
been ' 7.93 for the year ended March 31, 2025 (March 31, 2024: ' 5.33) and ' 7.87 for the
year ended March 31, 2025 (March 31, 2024: ' 5.31) respectively.
Performance evaluation of the Board as a whole, the Directors, the Chairman of the
Board and the Board Committees
The Company, with the approval of its Board Nomination and Remuneration Committee, has
put in place a framework for evaluation of the Board as a whole, the Directors, the
Chairman, and the Board Committees.
The performance evaluation was undertaken through an online survey portal, as follows:
a) Evaluation of Board as a whole: The performance of the Board was assessed on
parameters relating to roles, responsibilities and obligations of the Board and
functioning of the Committees including but not limited to assessing the quality, quantity
and timeliness of flow of information between the management and the Board that is
necessary for the Board to effectively and reasonably perform their duties.
b) Evaluation of Non-Independent Directors and other Non-Executive Directors: The
evaluation criteria for the Non-Independent Directors and other Non-Executive Directors
were based on their participation, contribution and offering guidance to the management in
their capacity as members of the Board/respective Board Committees, especially in the
areas of their expertise.
c) Evaluation of Chairman of the Board of Directors:
The evaluation criteria for the Chairman of the Board, besides the general criteria
adopted for assessment of all Directors, focuses incrementally on leadership abilities,
effective management of meetings and safeguarding the interest of the stakeholders. The
views of the Executive and Non-Executive Directors were taken into consideration, during
the evaluation of the Chairman.
d) Evaluation of the Board Committees: The
evaluation criteria for the Committees were based on effective discharge of its terms
of reference and their contribution to the functioning of the Board.
The Board Nomination and Remuneration Committee evaluated the performance of the
Whole-time Director i.e. Managing Director & CEO. The details about the evaluation of
the Whole-time Director are further provided under the section titled Compensation
policy and practices.
Directors and officers liability insurance policy
The Company has taken Directors and Officers Liability Insurance for all its Directors
and Officers.
General Body Meetings
The details of the last three Annual General Meetings (AGM) are as given below:
Financial Year ended |
Day, Date |
Start time |
Venue |
Twenty- second AGM |
Monday, June 27, 2022 |
3.00 p.m. |
Through Video Conference (VC)/ Other Audio Visual Means (OAVM). Deemed venue - Registered Office of the Company |
Twenty- third AGM |
Friday, July 28, 2023 |
3.00 p.m. |
Through Video Conference (VC)/ Other Audio Visual Means (OAVM). Deemed venue - Registered Office of the Company |
Twenty- fourth AGM |
Friday, June 28, 2024 |
3.00 p.m. |
Through Video Conference (VC)/ Other Audio Visual Means (OAVM). Deemed venue - Registered Office of the Company |
The following special resolutions were passed by the
members during the last three Annual General Meetings:
Annual General Meeting held on June 27, 2022
Re-appointment of Mr. R. K. Nair as an Independent Director of the Company for a
second term of five consecutive years commencing from July 25, 2022, till July 24, 2027.
Re-appointment of Mr. Dileep Choksi as an Independent Director of the Company
for a second term commencing from January 19, 2023 till December 25, 2024.
Annual General Meeting held on July 28, 2023
Re-appointment of Ms. Vibha Paul Rishi as an Independent Director of the Company
for a second term of five consecutive years commencing from January 1, 2024, till December
31, 2028.
Alteration of the Articles of Association of
the Company
Approval of the ICICI Prudential Life
Insurance Company Limited Employees Stock
Unit Scheme - 2023'
Approval of grant of employee stock units to the
employees of unlisted wholly-owned Subsidiary of the Company under ICICI
Prudential Life Insurance Company Limited Employees Stock
Unit Scheme - 2023'
Annual General Meeting held on June 28, 2024
No special resolutions were passed at the meeting.
Postal ballot
During FY2025, the Company had passed following
resolutions through postal ballot:
1. Special resolution for appointment of Mr. Suresh Vaswani as a non-executive
Independent Director of the Company for a term of five consecutive years commencing from
July 4, 2024 to July 3, 2029, vide postal ballot notice dated July 23, 2024. The
resolution is deemed to have been passed on the last date specified for remote e-voting
i.e. August 29, 2024. The details of the voting pattern are as follows:
Number |
% of votes |
Number of |
Number of |
% of votes |
% of votes |
of votes |
Polled on |
votes cast |
votes cast |
in favour |
against |
polled |
outstanding |
in favour |
against the on votes |
on votes |
|
shares |
of the Resolution |
Resolution |
polled |
polled |
1,310,375,082 |
90.88 |
1,310,266,638 |
108,444 |
99.99 |
0.01 |
2. Special resolution for appointment of Ms. Anuradha Bhatia as a non-executive
Independent Director of the Company, for a term of five consecutive years commencing from
March 12, 2025 to March 11, 2030, vide postal ballot notice dated March 12, 2025. The
resolution is deemed to have been passed on the last date specified for remote e-voting
i.e. April 18, 2025. The details of the voting pattern are as follows:
Number |
% of votes |
Number of |
Number of |
% of votes |
% of votes |
of votes |
Polled on |
votes cast |
votes cast |
in favour |
against |
polled |
outstanding |
in favour |
against the on votes |
on votes |
|
shares |
of the Resolution |
Resolution |
polled |
polled |
1,316,084,863 |
91.06 |
1,315,580,959 |
503,904 |
99.96 |
0.04 |
For the aforesaid resolutions passed through postal ballot, the Board of Directors of
the Company, had appointed Mr. Mitesh Dhabliwala of Parikh & Associates, Practicing
Company Secretaries, as the Scrutinizer for conducting the Postal Ballot e-voting process
in a fair and transparent manner.
The postal ballot was carried out as per the provisions of Sections 108 and 110 and
other applicable provisions of the CA2013, read with the Rules framed thereunder and
applicable circulars issued by the Ministry of Corporate Affairs from time to time.
The postal ballot notice(s) and results alongwith the scrutinizer's report were
submitted to the stock exchange(s) and displayed on the Company's website at www.iciciprulife.com.
Further, at present, no special resolution is proposed to be passed through postal
ballot.
Means of communication
It is the Company's belief that all stakeholders should have access to complete
information regarding its position to enable them to accurately assess its future
potential. The Company disseminates information on its operations and initiatives on a
regular basis. The Company's website (www.iciciprulife.com) serves as an important
information dissemination platform for all
its stakeholders, allowing them to access various details of the Company at their own
convenience. It provides comprehensive information about the Company including Company's
products, financial performance, Board of Directors and Board Committees, management/key
personnel, customer service related touch points, and other statutory/ public disclosures.
The Company's investor relations personnel respond to specific queries and play a
proactive role in disseminating information to both analysts and investors. All
information which could have a material bearing on the Company's share price is disclosed
to the Stock Exchanges as per applicable regulatory provisions. The information is also
disclosed to the National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) from
time to time in compliance with Listing Regulations and other applicable laws. The
financial and other information and various compliances as required/prescribed under the
Listing Regulations are filed electronically with NSE and BSE through NSE Electronic
Application Processing (NEAP) System and through BSE Listing Centre and are also available
on their respective websites in addition to the Company's website. Additionally,
information is also disseminated to BSE/NSE where required, through email.
The extract of the Company's quarterly financial results are published in the Financial
Express (Mumbai, Pune, Ahmedabad, New Delhi, Chandigarh, Lucknow, Kolkata, Bangalore,
Chennai, Hyderabad and Kochi editions) and Loksatta (Mumbai, Pune, Nagpur, Ahmednagar, New
Delhi, Aurangabad editions). The financial results, official news releases, analyst call
transcripts and presentations are also available on the Company's website at www.iciciprulife.com.
General Shareholder Information
The Annual General Meeting (AGM') is proposed to be convened through Video
Conference (VC) or/and Other Audio Visual Means (OAVM), in compliance with applicable
provisions of the CA2013 read with General Circular dated September 19, 2024 read with
General Circular dated September 25, 2023 issued by Ministry of Corporate Affairs (MCA)
and Circular dated October 3, 2024 issued by Securities and Exchange Board of India read
with earlier Circular(s) issued in this regard by the respective Authorities, Secretarial
Standard on General Meetings (SS-2) issued by the Institute of Company Secretaries of
India and any other applicable law, rules and regulations including any statutory
modification(s) or re-enactment(s) thereof for the time being in force. Considering the
same, the deemed venue for 25th AGM shall be the registered office of the
Company.
In view of the virtual AGM, the members are given the facility to attend and
participate in the AGM through Video Conference (VC)/ Other Audio Visual Means (OAVM), by
following the procedure mentioned in the Notice of the AGM.
General Body Meeting Day, Date & Time
Twenty fifth AGM Friday June 27, 2025 at 3:30 p.m.
Financial Year: April 1, 2024 to March 31, 2025
Book Closure: June 13, 2025 to June 27, 2025 (both days inclusive)
Dividend payment date: Within 30 days of the AGM
Self-Certification and Fit and Proper Declaration
Pursuant to IRDAI (Registration, Capital Structure, Transfer of Shares and Amalgamation
of Insurers) Regulations, 2024 (IRDAI Registration Regulations), read with its Master
Circular, in case of a Listed Insurance Company, a person/entity shall be required to:
i. Submit a Self-Certification, for transferring more than 1% but less than 5% of the
paid-up equity capital of the Company, immediately upon execution of the transaction.
ii. Take prior approval of IRDAI, for acquiring more than 5% of the paid-up equity
capital of the Company
Accordingly, the format of Self-Certification and Fit and Proper Declaration, IRDAI
Registration Regulations and its Master Circular has been hosted on the website of the
Company at https://www.iciciprulife.com/about-us/
shareholder-information/other.html?ID=about-other.
Business Responsibility and Sustainability Report, Environmental, Social and Governance
(ESG) and Conservation of Energy and Technology absorption
Business Responsibility and Sustainability Report (BRSR) as stipulated under Regulation
34 of the Listing Regulations has been hosted on the website of the Company and can be
viewed at https://www.iciciprulife. com/about-us/shareholder-information/other.html.
Reporting Criteria
The reporting criteria used by the Company to prepare the BRSR is issued under SEBI
Listing Regulations read with SEBI Master Circular dated November 11, 2024 (Master
Circular), SEBI Circular dated December 20, 2024 and SEBI Circular dated March 28, 2025,
the Guidance note for BRSR read with National Guidelines for Responsible Business Conduct
Issued by Ministry of Corporate Affairs.
Reasonable Assurance Report
The Reasonable Assurance Report of Walker Chandiok & Co., LLP is annexed to the
BRSR and shall form part of the Annual Report for FY2025.
The Company has an elaborate ESG Report that details the efforts of the Company on
sustainability and is also available on its website at https://www.iciciprulife.
com/about-us/investor-relations.html?ID = about1. The Company constantly undertakes
technology and digitalization initiatives and works with employees, partners and customers
to offer simple and robust technology solutions towards reducing the Company's carbon
footprint.
The Company has undertaken various initiatives for energy conservation at its premises
and has used information technology extensively in its operations, which includes
technological interventions in aspects pertaining to policy lifecycle, marketing &
lead generation, partner integration, analytics and assurance.
Digitisation
The Company has completely digitised its policy issuance and servicing operations. More
than 99% of our policies are logged in digitally. The Company has also given its customers
the facility of opening an e-insurance accounts, which is an electronic repository of
policies. This allows our customers to electronically store and manage their insurance
policies.
To the extent permitted, the Company communicates with its customer via SMS and email
to limit the usage of paper. Employees, advisors, and partners use our digital platforms.
Due to these initiatives, the Company's paper usage has decreased significantly over the
years. These measures and digital processes have not only increased speed and convenience
for employees, customers and distributors, but they have also had a good environmental
impact.
Maintenance of cost records
Being an Insurance Company, the maintenance of cost records, for the services rendered
by the Company, pursuant to Section 148(1) of the CA2013 read with Rule 3 of the Companies
(Cost Records and Audit) Rules, 2014, is not applicable.
Details of application made or any proceeding pending under the Insolvency and
Bankruptcy Code, 2016 during the year alongwith their status as at the end of the
financial year.
The Company has not filed any application for settlement nor are any such proceedings
pending under the Insolvency and Bankruptcy Code, 2016, against the Company, as at March
31, 2025.
Details of difference between amount of the valuation done at the time of one time
settlement and the valuation done while taking loan from the Banks or Financial
Institutions along with the reasons thereof.
The above is not applicable given that the Company has not filed any application for
settlement under the Insolvency and Bankruptcy Code, 2016 during the financial year ended
March 31, 2025.
Credit Rating during FY2025
Type of Instrument |
Name of the Rating Agency |
Rating assigned |
Date on which credit rating letter was obtained |
Unsecured, subordinated, listed, rated, |
ICRA Limited |
AAA(Stable) |
October 1, 2024 |
redeemable, taxable, non-cumulative, non-convertible debentures in the
nature of Subordinated Debt' aggregating to ' 12.00 billion |
CRISIL Limited |
AAA(Stable) |
September 2, 2024 |
Unsecured, subordinated, listed, rated, |
ICRA Limited |
AAA(Stable) |
December 2, 2024 |
redeemable, taxable, non-cumulative, non-convertible debentures in the
nature of Subordinated Debt' aggregating to ' 14.00 billion |
CRISIL Limited |
AAA(Stable) |
December 2, 2024 |
Foreign exchange earnings and outgo
Details of foreign exchange earnings and outgo required under section
134(3)(m) of the CA2013 read with rule 8(3) of the Companies (Accounts) Rules, 2014 are as
under:
|
|
(' billion) |
Particulars |
FY2024 |
FY2025 |
Foreign exchange earnings and outgo |
|
|
- Earnings |
0.30 |
0.60 |
- Outgo |
1.40 |
0.85 |
Commodity price risk or foreign exchange risk and hedging activities
None of the above is applicable to the Company as the Company neither undertakes any
commodities business nor has any exposure to foreign currencies that may require
implementing any hedging strategies.
Plant Locations
The Company has various branches across the country, however, there are no plants as
the Company is not a manufacturing entity.
Details of unclaimed suspense account as provided by our RTA i.e. KFin Technologies
Limited pursuant to Regulation 39 read with Part F of Schedule V
of Securities and Exchange Board of India (Listing Obligations and Disclosure
Requirements) Regulations, 2015.
No shares were lying in the unclaimed suspense account as of March 31, 2025.
Events after Balance Sheet date
There have been no material changes and commitments, affecting the financial position
of the Company, which have occurred between the end of the financial year of the Company
to which the Balance Sheet relates and the date of this Report.
Disclosures for FY2025:
(a) There are no materially significant related party transactions that may have
potential conflict of interest with the overall business operations of the Company.
(b) No penalties or strictures have been imposed on the Company by the Stock Exchanges,
the Securities & Exchange Board of India, Insurance Regulatory and Development
Authority of India or any other statutory authority, for any non-compliance on any matter
relating to capital markets, during the last three years.
(c) In terms of the Whistle Blower Policy of the Company, no employee of the Company
has been denied access to raising concerns through the mechanism of the Whistle Blower
policy.
(d) There are no agreements binding the Company under clause 5A of paragraph A of Part
A of Schedule III of Listing Regulations.
Adoption of mandatory and non-mandatory requirements
The Company has complied with all mandatory requirements specified in Regulations 17 to
27 and clauses (b) to (i) of sub regulation 2 of Regulation 46 and some of the
non-mandatory requirements pertaining to Corporate Governance stipulated under the Listing
Regulations. The Company has adopted non-mandatory requirement regarding the reporting
requirement of the internal auditor, which in the Company's instance, reports directly to
the Board Audit Committee.
Green Initiatives in Corporate Governance
In line with the Green Initiative', the Company has effected electronic delivery
of notice of Annual General Meeting, Postal Ballot and Annual Report to those Members
whose e-mail ids were registered with the respective Depository Participants and
downloaded from the depositories viz. National Securities Depository Limited/ Central
Depository Services (India) Limited. The CA2013 and the underlying rules as well as
Regulation 36 of the Listing Regulations, permit the dissemination of financial statements
and annual report in electronic mode to the Members. The Directors are thankful to the
Members for actively participating in the Green Initiative and seek their continued
support for effectively implementing the Green Initiative cause.
In order to support the cause, we have been regularly requesting Members to
register/update their email ids with their Depository Participants so as to enable the
Company to send various communication through electronic mode. We believe and endorse the
Green Initiative' as it would not only rationalise the use of paper but also ensure
prompt communication, avoid loss in transit and have reference value of the communication.
DETAILS PERTAINING TO SECURITIES Listing of securities on Stock Exchange
The Company has listed its securities on the following stock exchanges:
Stock Exchange |
Equity Code |
Debt Code |
BSE Limited (BSE) (Equity) Phiroze Jeejeebhoy Towers Dalal Street
Mumbai 400 001 |
540133 |
|
National Stock Exchange of India Limited (NSE) (Equity) Exchange
Plaza'
Bandra-Kurla Complex Bandra (East), Mumbai 400 051 |
ICICIPRULI |
ICPR30 and ICPR34 |
The Company has paid the annual listing fees for the relevant periods to BSE and NSE
where its equity shares are listed.
Share Transfer System
SEBI has mandated transfer of securities only in dematerialized form, except for
transmission and transposition of securities. The Share Transfer Systems of the Company is
managed by KFin Technologies Limited, Registrar and Share Transfer Agent (RTA) of the
Company. The address of the RTA is as follows:
KFin Technologies Limited
Ms. C Shobha Anand
Selenium Building, Tower-B, Plot No 31 & 32, Financial District,
Nanakramguda, Serilingampally, Hyderabad, Rangareddy, Telangana, India - 500 032.
Email ID: einward.ris@kfintech.com and shobha.anand@kfintech.com
Toll Free/ Phone Number: 1800 309 4001
KPRISM (Mobile Application): https://kprism.kfintech.com/
KFINTECH Corporate Website: https://www.kfintech.com RTA website: https://ris.kfintech.com
Investor Support Centre (DIY Link): https://ris.kfintech.com/clientservices/isc
KFin Technologies Limited, RTA of the Company, have in compliance with the SEBI
circular dated June 8, 2023, created an online application for processing investor service
request and complaints. The same can be accessed at https://ris.
kfintech.com/default.aspx# > Investor Services > Investor Support.
Debenture Trustees
Axis Trustee Services Limited
Registered Office: Axis House, Bombay Dyeing Mills Compound,
Pandhurang Budhkar Marg, Worli Mumbai - 400 025
Telephone Number: 022-6226 0054
Fax Number: 022-6226 0050
Email id: debenturetrustee@axistrustee.in
Website: www.axistrustee.in
Information on shareholding
Shareholding pattern of the Company as at March 31, 2025
Sr.
No. |
Category/Name of the Shareholder |
Number of shares on March 31, 2025 (in million) |
% Total |
1 |
ICICI Bank Limited (Promoter) |
737.61 |
51.03 |
2 |
Prudential Corporation Holdings Limited (Promoter) |
317.52 |
21.97 |
3 |
Foreign Institutional Investors /Foreign Portfolio Investors/Foreign
Bodies/Non-resident individuals |
222.92 |
15.42 |
4 |
Domestic Mutual Funds |
94.16 |
6.52 |
5. |
Retail Investors & Others |
35.43 |
2.45 |
6. |
Domestic Insurance Company |
21.84 |
1.51 |
7. |
Domestic Body corporates, Institutions, Trust & NBFC |
9.34 |
0.65 |
8. |
Alternative Investment Fund |
5.64 |
0.39 |
9. |
Domestic Banks |
0.87 |
0.06 |
|
Total |
1,445.32 |
100.00 |
Note: Employees of the Company hold 553,479 shares in the Company constituting to
0.039%
Shareholders of the Company with more than 1% holding as at March 31, 2025 (other than
promoters of the Company)
Sr.
No. |
Category/Name of the Shareholder |
Number of shares (in million) |
% to total |
1 |
Government of Singapore |
28.97 |
2.00 |
2 |
Compassvale Investments Pte. Ltd. |
28.72 |
1.99 |
3 |
Camas Investments Pte. Ltd. |
25.53 |
1.77 |
4 |
Government Pension Fund Global |
27.09 |
1.87 |
5 |
SBI mutual funds |
30.81 |
2.13 |
6 |
ICICI Prudential Mutual Funds |
27.99 |
1.94 |
Distribution of shareholding of the Company as at March 31, 2025
Distribution schedule at March 31, 2025 (Total) |
Sr. No |
Category |
No. of holders |
% of holders |
Number of shares |
% of equity |
1 |
1-5,000 |
326,118 |
96.96 |
19,576,834 |
1.36 |
2 |
5,001-10,000 |
5,218 |
1.55 |
3,763,218 |
0.26 |
3 |
10,001-20,000 |
2,323 |
0.69 |
3,318,097 |
0.23 |
4 |
20,001-30,000 |
716 |
0.21 |
1,775,830 |
0.12 |
5 |
30,001-40,000 |
341 |
0.10 |
1,187,149 |
0.08 |
6 |
40,001-50,000 |
227 |
0.07 |
1,034,163 |
0.07 |
7 |
50,001-100,000 |
465 |
0.14 |
3,327,671 |
0.23 |
8 |
100,001 and above |
942 |
0.28 |
1,411,338,794 |
97.65 |
|
TOTAL: |
336,350 |
100.00 |
1,445,321,756 |
100.00 |
The Company's equity shares are traded mainly in dematerialised form. At March 31,
2025, 100% of paid-up equity share capital is held in dematerialised form.
Increase in share capital
The paid-up capital of the Company increased by ' 47.06 million from the previous
financial year, consequent to allotment of shares resulting due to the exercise of stock
options granted under the Company's Employee Stock Option Scheme, and the paid-up capital
was ' 14,453.22 million at March 31, 2025.
Details of equity shares held by the non-executive Directors of the Company at March
31, 2025: Nil
Queries related to the operational and financial performance of the Company may be
addressed to:
Mr. Dhiraj Chugha Investor Relations Registered office:
ICICI Prudential Life Insurance Co. Ltd.
ICICI Prulife Towers, 1089, Appasaheb Marathe Marg,
Prabhadevi, Mumbai 400025
Telephone: (91 22) 40391600
Fax: (91 22) 2437 6638
Email id: ir@iciciprulife.com
Address for Correspondence
Ms. Priya Nair
Company Secretary and Compliance Officer
ICICI Prudential Life Insurance Company Limited
1089, ICICI Prulife Towers, Appasaheb Marathe Marg,
Prabhadevi, Mumbai - 400025
Telephone: (91 22) 4039 1600
Fax: (91 22) 2437 6638
Email id: investor@iciciprulife.com
COMPLIANCE CERTIFICATE OF THE AUDITORS
The Company has annexed to this Report (Annexure D), a certificate obtained from
the statutory auditors, Walker Chandiok & Co LLP, Chartered Accountants and M. P.
Chitale & Co, Chartered Accountants, regarding compliance of conditions of Corporate
Governance as stipulated in the Listing Regulations.
CERTIFICATE FROM A PRACTICING COMPANY SECRETARY
In terms of the Listing Regulations, the Company has obtained a Certificate from M/s.
Dholakia & Associates LLP, Company Secretaries, confirming that none of the Directors
on the Board of the Company have been debarred or disqualified from being appointed or
continuing as directors of companies by the Securities and Exchange Board of India,
Ministry of Corporate Affairs or any such statutory authority. The certificate of Company
Secretary in practice is annexed herewith as Annexure E.